```
* * * * * * RECONNECTED TO STN INTERNATIONAL * * * * * *
SESSION RESUMED IN FILE 'PHAR' AT 15:38:09 ON 24 JAN 2003
FILE 'PHAR' ENTERED AT 15:38:09 ON 24 JAN 2003
COPYRIGHT (C) 2003 PJB Publications Ltd. (PJB)
COST IN U.S. DOLLARS                                SINCE FILE      TOTAL
                                                         ENTRY    SESSION
FULL ESTIMATED COST                                      40.86     265.93

=> index bioscience medicine
FILE 'DRUGMONOG' ACCESS NOT AUTHORIZED
COST IN U.S. DOLLARS                                SINCE FILE      TOTAL
                                                         ENTRY    SESSION
FULL ESTIMATED COST                                      44.02     269.09

INDEX 'ADISCTI, ADISINSIGHT, ADISNEWS, AGRICOLA, ANABSTR, AQUASCI, BIOBUSINESS,
       BIOCOMMERCE, BIOSIS, BIOTECHABS, BIOTECHDS, BIOTECHNO, CABA, CANCERLIT,
       CAPLUS, CEABA-VTB, CEN, CIN, CONFSCI, CROPB, CROPU, DDFB, DDFU, DGENE,
       DRUGB, DRUGLAUNCH, DRUGMONOG2, ...' ENTERED AT 15:38:32 ON 24 JAN 2003

67 FILES IN THE FILE LIST IN STNINDEX

Enter SET DETAIL ON to see search term postings or to view
search error messages that display as 0* with SET DETAIL OFF.

=> s exendin and glucagon?
         44   FILE ADISCTI
          7   FILE ADISINSIGHT
          3   FILE ADISNEWS
          6   FILE AGRICOLA
          2   FILE AQUASCI
          2   FILE BIOBUSINESS
          2   FILE BIOCOMMERCE
        222   FILE BIOSIS
          0*  FILE BIOTECHABS
  10 FILES SEARCHED...
          3   FILE BIOTECHDS
         53   FILE BIOTECHNO
         15   FILE CABA
         27   FILE CANCERLIT
        194   FILE CAPLUS
         22   FILE CIN
          0*  FILE DDFU
  23 FILES SEARCHED...
       1185   FILE DGENE
          4   FILE DRUGNL
        116   FILE DRUGU
          4   FILE DRUGUPDATES
          5   FILE EMBAL
        147   FILE EMBASE
        117   FILE ESBIOBASE
          2   FILE FEDRIP
          2   FILE FROSTI
          2   FILE GENBANK
          8   FILE IFIPAT
          6   FILE JICST-EPLUS
         24   FILE LIFESCI
        156   FILE MEDLINE
  48 FILES SEARCHED...
         74   FILE PASCAL
          3   FILE PHAR
          4   FILE PHARMAML
         12   FILE PHIN
         31   FILE PROMT
        181   FILE SCISEARCH
         55   FILE TOXCENTER
```

```
        62   FILE USPATFULL
         4   FILE USPAT2
        25   FILE WPIDS
         0*  FILE WPINDEX
  64 FILES SEARCHED...
         1   FILE IPA
        18   FILE NLDB

  40 FILES HAVE ONE OR MORE ANSWERS,    67 FILES SEARCHED IN STNINDEX

L309 QUE EXENDIN AND GLUCAGON?

=> file hits
COST IN U.S. DOLLARS                                  SINCE FILE      TOTAL
                                                         ENTRY    SESSION
FULL ESTIMATED COST                                      31.35     300.44

FILE 'DGENE' ENTERED AT 16:12:37 ON 24 JAN 2003
COPYRIGHT (C) 2003 THOMSON DERWENT

FILE 'BIOSIS' ENTERED AT 16:12:37 ON 24 JAN 2003
COPYRIGHT (C) 2003 BIOLOGICAL ABSTRACTS INC.(R)

FILE 'CAPLUS' ENTERED AT 16:12:37 ON 24 JAN 2003
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2003 AMERICAN CHEMICAL SOCIETY (ACS)

FILE 'SCISEARCH' ENTERED AT 16:12:37 ON 24 JAN 2003
COPYRIGHT (C) 2003 Institute for Scientific Information (ISI) (R)

FILE 'MEDLINE' ENTERED AT 16:12:37 ON 24 JAN 2003

FILE 'EMBASE' ENTERED AT 16:12:37 ON 24 JAN 2003
COPYRIGHT (C) 2003 Elsevier Science B.V.  All rights reserved.

FILE 'ESBIOBASE' ENTERED AT 16:12:37 ON 24 JAN 2003
COPYRIGHT (C) 2003 Elsevier Science B.V., Amsterdam. All rights reserved.

FILE 'DRUGU' ENTERED AT 16:12:37 ON 24 JAN 2003
COPYRIGHT (C) 2003 THOMSON DERWENT

FILE 'PASCAL' ENTERED AT 16:12:37 ON 24 JAN 2003
Any reproduction or dissemination in part or in full,
by means of any process and on any support whatsoever
is prohibited without the prior written agreement of INIST-CNRS.
COPYRIGHT (C) 2003 INIST-CNRS. All rights reserved.

FILE 'USPATFULL' ENTERED AT 16:12:37 ON 24 JAN 2003
CA INDEXING COPYRIGHT (C) 2003 AMERICAN CHEMICAL SOCIETY (ACS)

FILE 'TOXCENTER' ENTERED AT 16:12:37 ON 24 JAN 2003
COPYRIGHT (C) 2003 ACS

FILE 'BIOTECHNO' ENTERED AT 16:12:37 ON 24 JAN 2003
COPYRIGHT (C) 2003 Elsevier Science B.V., Amsterdam. All rights reserved.

FILE 'ADISCTI' ENTERED AT 16:12:37 ON 24 JAN 2003
COPYRIGHT (C) 2003 Adis International Ltd. (ADIS)

FILE 'PROMT' ENTERED AT 16:12:37 ON 24 JAN 2003
COPYRIGHT (C) 2003 Gale Group. All rights reserved.

FILE 'CANCERLIT' ENTERED AT 16:12:37 ON 24 JAN 2003
```

FILE 'WPIDS' ENTERED AT 16:12:37 ON 24 JAN 2003
COPYRIGHT (C) 2003 THOMSON DERWENT

FILE 'LIFESCI' ENTERED AT 16:12:37 ON 24 JAN 2003
COPYRIGHT (C) 2003 Cambridge Scientific Abstracts (CSA)

FILE 'CIN' ENTERED AT 16:12:37 ON 24 JAN 2003
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2003 American Chemical Society (ACS)

FILE 'NLDB' ENTERED AT 16:12:37 ON 24 JAN 2003
COPYRIGHT (C) 2003 Gale Group. All rights reserved.

FILE 'CABA' ENTERED AT 16:12:37 ON 24 JAN 2003
COPYRIGHT (C) 2003 CAB INTERNATIONAL (CABI)

FILE 'PHIN' ENTERED AT 16:12:37 ON 24 JAN 2003
COPYRIGHT (C) 2003 PJB Publications Ltd. (PJB)

FILE 'IFIPAT' ENTERED AT 16:12:37 ON 24 JAN 2003
COPYRIGHT (C) 2003 IFI CLAIMS(R) Patent Services (IFI)

FILE 'ADISINSIGHT' ENTERED AT 16:12:37 ON 24 JAN 2003
COPYRIGHT (C) 2003 Adis International Ltd. (ADIS)

FILE 'AGRICOLA' ENTERED AT 16:12:37 ON 24 JAN 2003

FILE 'JICST-EPLUS' ENTERED AT 16:12:37 ON 24 JAN 2003
COPYRIGHT (C) 2003 Japan Science and Technology Corporation (JST)

FILE 'EMBAL' ENTERED AT 16:12:37 ON 24 JAN 2003
COPYRIGHT (C) 2003 Elsevier Science B.V. All rights reserved.

FILE 'DRUGNL' ENTERED AT 16:12:37 ON 24 JAN 2003
COPYRIGHT (C) 2003 IMSWORLD Publications Ltd

FILE 'DRUGUPDATES' ENTERED AT 16:12:37 ON 24 JAN 2003
COPYRIGHT (C) 2003 IMSWORLD Publications Ltd

FILE 'PHARMAML' ENTERED AT 16:12:37 ON 24 JAN 2003
Copyright 2003 (c) MARKETLETTER Publications Ltd. All rights reserved.

FILE 'USPAT2' ENTERED AT 16:12:37 ON 24 JAN 2003
CA INDEXING COPYRIGHT (C) 2003 AMERICAN CHEMICAL SOCIETY (ACS)

FILE 'ADISNEWS' ENTERED AT 16:12:37 ON 24 JAN 2003
COPYRIGHT (C) 2003 Adis International Ltd. (ADIS)

FILE 'BIOTECHDS' ENTERED AT 16:12:37 ON 24 JAN 2003
COPYRIGHT (C) 2003 THOMSON DERWENT AND INSTITUTE FOR SCIENTIFIC INFORMATION

FILE 'PHAR' ENTERED AT 16:12:37 ON 24 JAN 2003
COPYRIGHT (C) 2003 PJB Publications Ltd. (PJB)

FILE 'AQUASCI' ENTERED AT 16:12:37 ON 24 JAN 2003
(c) 2003 FAO (on behalf of the ASFA Advisory Board) All rights reserved.

FILE 'BIOBUSINESS' ENTERED AT 16:12:37 ON 24 JAN 2003
COPYRIGHT (C) 2003 Biological Abstracts, Inc. (BIOSIS)

FILE 'BIOCOMMERCE' ENTERED AT 16:12:37 ON 24 JAN 2003
COPYRIGHT (C) 2003 BioCommerce Data Ltd. Richmond Surrey, United Kingdom. All rights reserved

FILE 'FEDRIP' ENTERED AT 16:12:37 ON 24 JAN 2003

FILE 'FROSTI' ENTERED AT 16:12:37 ON 24 JAN 2003
COPYRIGHT (C) 2003 Leatherhead Food Research Association

FILE 'GENBANK' ENTERED AT 16:12:37 ON 24 JAN 2003

FILE 'IPA' ENTERED AT 16:12:37 ON 24 JAN 2003
COPYRIGHT (C) 2003 American Society of Hospital Pharmacists (ASHP)

=> s l309
L310 1185 FILE DGENE
L311 222 FILE BIOSIS
L312 194 FILE CAPLUS
L313 181 FILE SCISEARCH
L314 156 FILE MEDLINE
L315 147 FILE EMBASE
L316 117 FILE ESBIOBASE
L317 116 FILE DRUGU
L318 74 FILE PASCAL
L319 62 FILE USPATFULL
L320 55 FILE TOXCENTER
L321 53 FILE BIOTECHNO
L322 44 FILE ADISCTI
L323 31 FILE PROMT
L324 27 FILE CANCERLIT
L325 25 FILE WPIDS
L326 24 FILE LIFESCI
L327 22 FILE CIN
L328 18 FILE NLDB
L329 15 FILE CABA
L330 12 FILE PHIN
L331 8 FILE IFIPAT
L332 7 FILE ADISINSIGHT
L333 6 FILE AGRICOLA
L334 6 FILE JICST-EPLUS
L335 5 FILE EMBAL
L336 4 FILE DRUGNL
L337 4 FILE DRUGUPDATES
L338 4 FILE PHARMAML
L339 4 FILE USPAT2
L340 3 FILE ADISNEWS
L341 3 FILE BIOTECHDS
L342 3 FILE PHAR
L343 2 FILE AQUASCI
L344 2 FILE BIOBUSINESS
L345 2 FILE BIOCOMMERCE
L346 2 FILE FEDRIP
L347 2 FILE FROSTI
L348 2 FILE GENBANK
L349 1 FILE IPA

TOTAL FOR ALL FILES
L350 2850 L309

=> s exendin (s) glucagon
L351 935 FILE DGENE
L352 176 FILE BIOSIS
L353 105 FILE CAPLUS
L354 158 FILE SCISEARCH
L355 139 FILE MEDLINE
L356 126 FILE EMBASE
L357 111 FILE ESBIOBASE
L358 63 FILE DRUGU

```
L359         67 FILE PASCAL
L360         46 FILE USPATFULL
L361         27 FILE TOXCENTER
L362         48 FILE BIOTECHNO
L363         28 FILE ADISCTI
L364         20 FILE PROMT
L365         23 FILE CANCERLIT
L366         20 FILE WPIDS
L367         24 FILE LIFESCI
L368         20 FILE CIN
L369         14 FILE NLDB
L370         14 FILE CABA
L371          7 FILE PHIN
L372          3 FILE IFIPAT
L373          7 FILE ADISINSIGHT
L374          4 FILE AGRICOLA
L375          5 FILE JICST-EPLUS
L376          4 FILE EMBAL
L377          3 FILE DRUGNL
L378          3 FILE DRUGUPDATES
L379          4 FILE PHARMAML
L380          3 FILE USPAT2
L381          3 FILE ADISNEWS
L382          3 FILE BIOTECHDS
L383          1 FILE PHAR
L384          2 FILE AQUASCI
L385          0 FILE BIOBUSINESS
L386          2 FILE BIOCOMMERCE
PROXIMITY OPERATOR LEVEL NOT CONSISTENT WITH
FIELD CODE - 'AND' OPERATOR ASSUMED 'EXENDIN (S) GLUCAGON'
L387          2 FILE FEDRIP
L388          2 FILE FROSTI
L389          0 FILE GENBANK
L390          1 FILE IPA

TOTAL FOR ALL FILES
L391       2223 EXENDIN (S) GLUCAGON

=> s L391 and exendin-4 and glucagon
L392        396 FILE DGENE
L393        103 FILE BIOSIS
L394         77 FILE CAPLUS
L395        109 FILE SCISEARCH
L396         84 FILE MEDLINE
L397         75 FILE EMBASE
L398         65 FILE ESBIOBASE
L399         52 FILE DRUGU
L400         41 FILE PASCAL
L401         34 FILE USPATFULL
L402         22 FILE TOXCENTER
L403         30 FILE BIOTECHNO
L404         26 FILE ADISCTI
L405         13 FILE PROMT
L406         14 FILE CANCERLIT
L407         14 FILE WPIDS
L408         12 FILE LIFESCI
L409         18 FILE CIN
L410         10 FILE NLDB
L411          4 FILE CABA
L412          6 FILE PHIN
L413          3 FILE IFIPAT
L414          5 FILE ADISINSIGHT
L415          2 FILE AGRICOLA
L416          2 FILE JICST-EPLUS
L417          4 FILE EMBAL
```

```
L418          3 FILE DRUGNL
L419          3 FILE DRUGUPDATES
L420          4 FILE PHARMAML
L421          2 FILE USPAT2
L422          2 FILE ADISNEWS
L423          1 FILE BIOTECHDS
L424          1 FILE PHAR
L425          1 FILE AQUASCI
L426          0 FILE BIOBUSINESS
L427          1 FILE BIOCOMMERCE
L428          2 FILE FEDRIP
L429          1 FILE FROSTI
L430          0 FILE GENBANK
L431          1 FILE IPA

TOTAL FOR ALL FILES
L432       1243 L391 AND EXENDIN-4 AND GLUCAGON

=> s l432 and glucagonoma
L433          0 FILE DGENE
L434          0 FILE BIOSIS
L435          1 FILE CAPLUS
L436          0 FILE SCISEARCH
L437          0 FILE MEDLINE
L438          0 FILE EMBASE
L439          0 FILE ESBIOBASE
L440          0 FILE DRUGU
L441          0 FILE PASCAL
L442          1 FILE USPATFULL
L443          0 FILE TOXCENTER
L444          0 FILE BIOTECHNO
L445          0 FILE ADISCTI
L446          0 FILE PROMT
L447          0 FILE CANCERLIT
L448          2 FILE WPIDS
L449          0 FILE LIFESCI
L450          0 FILE CIN
L451          0 FILE NLDB
L452          0 FILE CABA
L453          0 FILE PHIN
L454          1 FILE IFIPAT
L455          0 FILE ADISINSIGHT
L456          0 FILE AGRICOLA
L457          0 FILE JICST-EPLUS
L458          0 FILE EMBAL
L459          0 FILE DRUGNL
L460          0 FILE DRUGUPDATES
L461          0 FILE PHARMAML
L462          0 FILE USPAT2
L463          0 FILE ADISNEWS
L464          0 FILE BIOTECHDS
L465          0 FILE PHAR
L466          0 FILE AQUASCI
L467          0 FILE BIOBUSINESS
L468          0 FILE BIOCOMMERCE
L469          0 FILE FEDRIP
L470          0 FILE FROSTI
L471          0 FILE GENBANK
L472          0 FILE IPA

TOTAL FOR ALL FILES
L473          5 L432 AND GLUCAGONOMA

=> d l473 1-4 ibib abs
```

L473 ANSWER 1 OF 5 CAPLUS COPYRIGHT 2003 ACS
ACCESSION NUMBER: 2000:493318 CAPLUS
DOCUMENT NUMBER: 133:129880
TITLE: Methods using an **exendin** or related substance for **glucagon** suppression
INVENTOR(S): Young, Andrew; Gedulin, Bronislava
PATENT ASSIGNEE(S): Amylin Pharmaceuticals, Inc., USA
SOURCE: PCT Int. Appl., 96 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 3
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2000041548	A2	20000720	WO 2000-US942	20000114
WO 2000041548	A3	20001130		
W: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, DM, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, GM, KE, LS, MW, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
EP 1143989	A2	20011017	EP 2000-902415	20000114
EP 1143989	A3	20020911		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO				
BR 2000007823	A	20011120	BR 2000-7823	20000114
JP 2002538084	T2	20021112	JP 2000-593169	20000114
NO 2001003469	A	20010914	NO 2001-3469	20010712

PRIORITY APPLN. INFO.:
US 1999-116380P P 19990114
US 1999-132017P P 19990430
US 2000-175365P P 20000110
WO 2000-US942 W 20000114

AB Methods are provided for use of an **exendin**, an **exendin** agonist, or a modified **exendin** or **exendin** agonist having an **exendin** or **exendin** agonist linked to one or more polyethylene glycol polymers, for example, for lowering **glucagon** levels and/or suppressing **glucagon** secretion in a subject. These methods are useful in treating hyperglucagonemia and other conditions that would be benefited by lowering plasma **glucagon** or suppressing **glucagon** secretion.

L473 ANSWER 2 OF 5 USPATFULL
ACCESSION NUMBER: 2003:4123 USPATFULL
TITLE: Use of glycogen phosphorylase inhibitors
INVENTOR(S): Treadway, Judith L., Mystic, CT, UNITED STATES

	NUMBER	KIND	DATE	
PATENT INFORMATION:	US 2003004162	A1	20030102	
APPLICATION INFO.:	US 2001-813335	A1	20010320	(9)

	NUMBER	DATE
PRIORITY INFORMATION:	US 2000-191381P	20000322 (60)

DOCUMENT TYPE: Utility
FILE SEGMENT: APPLICATION
LEGAL REPRESENTATIVE: Gregg C. Benson, Pfizer Inc., Patent Department, MS 4159,, Eastern Point Road, Groton, CT, 06340
NUMBER OF CLAIMS: 23

EXEMPLARY CLAIM: 1
LINE COUNT: 4011
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The invention provides methods of treating prophylactically an individual in whom Type 2 diabetes mellitus has not yet presented, but in whom there is an increased risk of developing such condition, which methods comprise administering to an individual in need thereof an effective amount of a glycogen phosphorylase inhibitor; effective amounts of a glycogen phosphorylase inhibitor and a non-glycogen phosphorylase inhibiting anti-diabetic agent; or effective amounts of a glycogen phosphorylase inhibitor and an anti-obesity agent.

The invention further provides methods of treating prophylactically an individual in whom Type 2 diabetes mellitus has not yet presented, but in whom there is an increased risk of developing such condition, which methods comprise administering to an individual in need thereof a pharmaceutical composition comprising effective amounts of a glycogen phosphorylase inhibitor and a non-glycogen phosphorylase inhibiting anti-diabetic agent; or effective amounts of a glycogen phosphorylase inhibitor and an anti-obesity agent.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L473 ANSWER 3 OF 5 WPIDS (C) 2003 THOMSON DERWENT
ACCESSION NUMBER: 2002-012518 [02] WPIDS
CROSS REFERENCE: 2000-595483 [50]; 2000-680964 [50]
DOC. NO. CPI: C2002-003289
TITLE: Use of glycogen phosphorylase inhibitor in prophylactic treatment of Type II diabetes.
DERWENT CLASS: B02
INVENTOR(S): TREADWAY, J L
PATENT ASSIGNEE(S): (PFIZ) PFIZER PROD INC; (TREA-I) TREADWAY J L
COUNTRY COUNT: 34
PATENT INFORMATION:

PATENT NO	KIND	DATE	WEEK	LA	PG
EP 1136071	A2	20010926	(200202)*	EN	78
R: AL AT BE CH CY DE DK ES FI FR GB GR IE IT LI LT LU LV MC MK NL PT RO SE SI TR					
AU 2001028130	A	20010927	(200202)		
CA 2341344	A1	20010922	(200203)	EN	
JP 2001302546	A	20011031	(200204)		70
HU 2001001158	A2	20020228	(200223)		
KR 2001092696	A	20011026	(200223)		
NZ 510677	A	20021025	(200274)		
US 2003004162	A1	20030102	(200305)		
ZA 2001002318	A	20021127	(200305)		154

APPLICATION DETAILS:

PATENT NO	KIND		APPLICATION	DATE
EP 1136071	A2		EP 2001-301979	20010305
AU 2001028130	A		AU 2001-28130	20010320
CA 2341344	A1		CA 2001-2341344	20010320
JP 2001302546	A		JP 2001-78839	20010319
HU 2001001158	A2		HU 2001-1158	20010321
KR 2001092696	A		KR 2001-14306	20010320
NZ 510677	A		NZ 2001-510677	20010321
US 2003004162	A1	Provisional	US 2000-191381P	20000322
			US 2001-813335	20010320
ZA 2001002318	A		ZA 2001-2318	20010320

PRIORITY APPLN. INFO: US 2000-191381P 20000322; US 2001-813335 20010320

AN 2002-012518 [02] WPIDS

CR 2000-595483 [50]; 2000-680964 [50]

AB EP 1136071 A UPAB: 20020114

NOVELTY - A glycogen phosphorylase inhibitor (G1) is used in the manufacture of a medicament for prophylactically treating an individual with increased risk of developing Type II diabetes mellitus

DETAILED DESCRIPTION - INDEPENDENT CLAIMS are also included for the following:

(1) a pharmaceutical composition comprising (G1) and a non-glycogen phosphorylase inhibiting anti-diabetic agent (NG1); and

(2) a pharmaceutical composition comprising (G1) and an anti-obesity agent.

ACTIVITY - Antidiabetic.

MECHANISM OF ACTION - Glycogen phosphorylase inhibitor.

No biological data is given.

USE - For prophylactically treating a person having risk associated with Type 2 diabetes (particularly risk associated with insulin resistance and/or hyperinsulinemia; environmental or genetic Type 2 diabetes predisposing disease states or conditions (e.g. person with a family history of diabetes); race and/or ethnicity (e.g. individuals from African-American, Hispanic, Native American, Asian, or Pacific Islander population); genetic mutations affecting beta -cell function (e.g. defect on chromosome 12, gene HNF-1 alpha (MODY3), chromosome 7, gene glucokinase (MODY2), chromosome 20, gene HNF-4a (MODY1), or mitochondrial DNA); genetic defects in insulin action (e.g. genetic mutation leading to Type A insulin resistance, acanthosis nigricans, leprechaunism, Rabson-Mendenhall syndrome, lipoatrophic diabetes, or a genetic mutation or mutations in the insulin receptor, IRS proteins, glucose transporters, PC-1, glucokinase, UCP-1, beta 3 adrenergic receptor gene); presence of excess adipose tissue or clinically diagnosed obesity (e.g. central obesity); clinical chemistry or diagnostic testing signifying a pre-diabetic state (e.g. impaired glucose tolerance, impaired fasting glucose, or hyperglycemia relative to normoglycemia); physiologic and endocrine changes associated with growth, development, or aging (e.g. menopausal, pubescent, or aged individuals); diet or eating behaviors (e.g consumption of high fat or high carbohydrate diets, experiencing prolonged fasting or starvation, having anorexia nervosa and bulemia); abnormal cardiovascular or blood lipid parameters (e.g. hypertension, HDL cholesterol level upto 35 mg/dl and/or TG levels of at least 250 mg/dl and metabolic syndrome); reproductive status (e.g. pregnancy, a history of gestational diabetes and macrosomia); muscle wasting (e.g. aging, starvation, exposure to anti-gravity environments and paralysis resulting from spinal cord injury); polycystic ovary syndrome; organ disease or dysfunction (e.g. liver cirrhosis and renal disease); metabolic disturbances; endocrine disorders or endocrinopathies (e.g. hyperandrogenism, thyrotoxicosis, hyperthyroidism, insulinoma, **glucagonoma**, somatostatinoma, aldosteroma, Cushing's Syndrome, pheochromocytoma, acromegaly and hypercortisolemia); pathophysiologic states (e.g. infection, congenital rubella, cytomegalovirus, toxemia, uremia, sepsis and trauma); immune-mediated disease (e.g. stiff man syndrome or the production of anti-insulin receptor antibodies); drug or chemical exposure (e.g. glucocorticoids, cytokines, alpha -interferon, thyroid hormone, TNF alpha , thiazides, estrogen-containing products, beta -blockers, nicotinic acid, serotonin receptor-targeted antipsychotics or antidepressants, vacor, diazoxide, dilantin, and HIV protease inhibitors); genetic syndrome associated with diabetes (e.g. Down's Syndrome, Klinefelter's Syndrome, Wolfram's Syndrome, Freidreich's Syndrome, Huntington's chorea, Laurence-Moon-Biedl Syndrome, myotonic dystrophy, porphyria, Prader-Willi Syndrome and Alzheimer's Disease); and detrimental effects caused by the administration of prolonged, elevated doses of insulin and/or the presence of ketoacidosis) (all claimed).

Dwg.0/0

ACCESSION NUMBER: 2000-490999 [43] WPIDS
CROSS REFERENCE: 2000-514584 [46]; 2001-514422 [56]
DOC. NO. CPI: C2000-147547
TITLE: Lowering plasma **glucagon** using **exendin** , an **exendin** agonist, a modified **exendin** or a modified **exendin** agonist, useful for treating hyperglucagonemia and diabetes.
DERWENT CLASS: A25 A96 B04
INVENTOR(S): GEDULIN, B; YOUNG, A
PATENT ASSIGNEE(S): (AMYL-N) AMYLIN PHARM INC
COUNTRY COUNT: 91
PATENT INFORMATION:

PATENT NO	KIND	DATE	WEEK	LA	PG
WO 2000041548	A2	20000720	(200043)*	EN	96
RW: AT BE CH CY DE DK EA ES FI FR GB GH GM GR IE IT KE LS LU MC MW NL OA PT SD SE SL SZ TZ UG ZW					
W: AE AL AM AT AU AZ BA BB BG BR BY CA CH CN CR CU CZ DE DK DM EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW					
AU 2000024136	A	20000801	(200054)		
NO 2001003469	A	20010914	(200163)		
EP 1143989	A2	20011017	(200169)	EN	
R: AL AT BE CH CY DE DK ES FI FR GB GR IE IT LI LT LU LV MC MK NL PT RO SE SI					
BR 2000007823	A	20011120	(200202)		
KR 2001086165	A	20010908	(200219)		
KR 2002001719	A	20020109	(200246)		
CN 1347327	A	20020501	(200252)		
JP 2002538084	W	20021112	(200275)		104

APPLICATION DETAILS:

PATENT NO	KIND	APPLICATION	DATE
WO 2000041548	A2	WO 2000-US942	20000114
AU 2000024136	A	AU 2000-24136	20000114
NO 2001003469	A	WO 2000-US942	20000114
		NO 2001-3469	20010712
EP 1143989	A2	EP 2000-902415	20000114
		WO 2000-US942	20000114
BR 2000007823	A	BR 2000-7823	20000114
		WO 2000-US942	20000114
KR 2001086165	A	KR 2001-708904	20010713
KR 2002001719	A	WO 2000-US942	20000114
		KR 2001-708892	20010713
CN 1347327	A	CN 2000-805017	20000114
JP 2002538084	W	JP 2000-593169	20000114
		WO 2000-US942	20000114

FILING DETAILS:

PATENT NO	KIND		PATENT NO
AU 2000024136	A	Based on	WO 200041548
EP 1143989	A2	Based on	WO 200041548
BR 2000007823	A	Based on	WO 200041548
KR 2002001719	A	Based on	WO 200041548
JP 2002538084	W	Based on	WO 200041548

PRIORITY APPLN. INFO: US 2000-175365P 20000110; US 1999-116380P 19990114; US 1999-132017P 19990430
AN 2000-490999 [43] WPIDS

CR 2000-514584 [46]; 2001-514422 [56]
AB WO 200041548 A UPAB: 20021120
NOVELTY - A new method for lowering plasma **glucagon** comprises administering a compound (C1) selected from **exendin**, an **exendin** agonist, a modified **exendin** or a modified **exendin** agonist.

ACTIVITY - Antidiabetic; dermatological.

MECHANISM OF ACTION - The compounds lower plasma **glucagon** level.

The safety, tolerability, and efficacy of synthetic **exendin -4** was evaluated in 8 male non-insulin using patients with type 2 diabetes who had discontinued other antidiabetic therapy for a minimum of 7 days. Each patient received subcutaneous (SC) injections of placebo (PBO) and 0.1, 0.2, and 0.3 micro g/kg **exendin-4** 48 hours apart in a single-blind, dose-rising, placebo controlled crossover design. Five patients also received a 0.4 micro g/kg dose. Plasma glucose, insulin and **glucagon** concentrations were assessed during fasting and in response to a 7 Kcal/kg Sustacal (RTM) challenge administered at the time of **exendin-4**/PBO injection. Gastric emptying was evaluated by measuring serum acetaminophen concentrations following a 20 mg/kg oral dose of liquid acetaminophen administered with the Sustacal (RTM).

No safety issues were identified based upon reported adverse events, EKG (undefined) and safety lab monitoring. Doses of 0.3 and 0.4 micro g/kg elicited a dose-dependent increase in nausea. Vomiting occurred at the highest dose.

Plasma glucose concentrations were reduced in all doses of **exendin-4** compared to PBO although insulin concentrations were not significantly different. The 8 hour mean plus or minus SE changes in plasma glucose AUC (undefined) from baseline were +391 plus or minus 187, -263 plus or minus 108, -247 plus or minus 64, -336 plus or minus 139, and -328 plus or minus 70 (mg)(hr)/dL for the PBO, 0.1, 0.2, 0.3, and 0.4 micro g/kg doses respectively. The 3 hour changes in plasma **glucagon** were +128.0 plus or minus 19.2, -5.6 plus or minus 10.5, -29.4 plus or minus 18.6, -40.5 plus or minus 24.5, and +6.9 plus or minus 38.6 (pg)(hr)/mL respectively. The gastric emptying rate was slowed in all doses and the mean total absorbed acetaminophen over 6 hours was reduced by 51%, 50%, 57% and 79% compared to PBO for 0.1, 0.2, 0.3, and 0.4 micro g/kg doses respectively.

In summary, SC injection of **exendin-4** to patients identified no safety issues, was tolerated at doses at most 0.3 micro g/kg, reduced plasma glucose and **glucagon** and slowed the rate of gastric emptying.

USE - The method is useful for lowering plasma **glucagon** in subjects, preferably humans, suffering from necrolytic erythema or **glucagonoma** (claimed). The method is also useful for treating hyperglucagonemia and other conditions that would benefit from reduced **glucagon** levels and/or suppression of **glucagon**, e.g. type 1 and type 2 diabetes.

Dwg.0/6

```
=> dup rem l432
DUPLICATE IS NOT AVAILABLE IN 'DGENE, ADISINSIGHT, DRUGUPDATES, PHARMAML,
ADISNEWS, PHAR, BIOCOMMERCE, FEDRIP, GENBANK'.
ANSWERS FROM THESE FILES WILL BE CONSIDERED UNIQUE
PROCESSING IS APPROXIMATELY  87% COMPLETE FOR L432
PROCESSING COMPLETED FOR L432
L474         737 DUP REM L432 (506 DUPLICATES REMOVED)

=> s l474 (s) (glucagon (w) secretion)
L475         396 S L474
PROXIMITY OPERATOR LEVEL NOT CONSISTENT WITH
FIELD CODE - 'AND' OPERATOR ASSUMED 'L475 (S) '
L476           2 FILE DGENE
```

```
L477       103 S L474
PROXIMITY OPERATOR LEVEL NOT CONSISTENT WITH
FIELD CODE - 'AND' OPERATOR ASSUMED 'L477 (S) '
L478         7 FILE BIOSIS
L479        30 S L474
PROXIMITY OPERATOR LEVEL NOT CONSISTENT WITH
FIELD CODE - 'AND' OPERATOR ASSUMED 'L479 (S) '
L480         2 FILE CAPLUS
L481        27 S L474
PROXIMITY OPERATOR LEVEL NOT CONSISTENT WITH
FIELD CODE - 'AND' OPERATOR ASSUMED 'L481 (S) '
L482         2 FILE SCISEARCH
L483         4 S L474
PROXIMITY OPERATOR LEVEL NOT CONSISTENT WITH
FIELD CODE - 'AND' OPERATOR ASSUMED 'L483 (S) '
L484         0 FILE MEDLINE
L485         0 S L474
PROXIMITY OPERATOR LEVEL NOT CONSISTENT WITH
FIELD CODE - 'AND' OPERATOR ASSUMED 'L485 (S) '
L486         0 FILE EMBASE
L487         7 S L474
PROXIMITY OPERATOR LEVEL NOT CONSISTENT WITH
FIELD CODE - 'AND' OPERATOR ASSUMED 'L487 (S) '
L488         1 FILE ESBIOBASE
L489        34 S L474
PROXIMITY OPERATOR LEVEL NOT CONSISTENT WITH
FIELD CODE - 'AND' OPERATOR ASSUMED 'L489 (S) '
L490         6 FILE DRUGU
L491         6 S L474
PROXIMITY OPERATOR LEVEL NOT CONSISTENT WITH
FIELD CODE - 'AND' OPERATOR ASSUMED 'L491 (S) '
L492         0 FILE PASCAL
L493        34 S L474
PROXIMITY OPERATOR LEVEL NOT CONSISTENT WITH
FIELD CODE - 'AND' OPERATOR ASSUMED 'L493 (S) '
L494        13 FILE USPATFULL
L495         2 S L474
PROXIMITY OPERATOR LEVEL NOT CONSISTENT WITH
FIELD CODE - 'AND' OPERATOR ASSUMED 'L495 (S) '
L496         0 FILE TOXCENTER
L497         0 S L474
PROXIMITY OPERATOR LEVEL NOT CONSISTENT WITH
FIELD CODE - 'AND' OPERATOR ASSUMED 'L497 (S) '
L498         0 FILE BIOTECHNO
L499        24 S L474
PROXIMITY OPERATOR LEVEL NOT CONSISTENT WITH
FIELD CODE - 'AND' OPERATOR ASSUMED 'L499 (S) '
L500         7 FILE ADISCTI
L501        13 S L474
PROXIMITY OPERATOR LEVEL NOT CONSISTENT WITH
FIELD CODE - 'AND' OPERATOR ASSUMED 'L501 (S) '
L502         2 FILE PROMT
L503         0 S L474
PROXIMITY OPERATOR LEVEL NOT CONSISTENT WITH
FIELD CODE - 'AND' OPERATOR ASSUMED 'L503 (S) '
L504         0 FILE CANCERLIT
L505         7 S L474
PROXIMITY OPERATOR LEVEL NOT CONSISTENT WITH
FIELD CODE - 'AND' OPERATOR ASSUMED 'L505 (S) '
L506         0 FILE WPIDS
L507         0 S L474
PROXIMITY OPERATOR LEVEL NOT CONSISTENT WITH
FIELD CODE - 'AND' OPERATOR ASSUMED 'L507 (S) '
L508         0 FILE LIFESCI
L509        18 S L474
```

PROXIMITY OPERATOR LEVEL NOT CONSISTENT WITH
FIELD CODE - 'AND' OPERATOR ASSUMED 'L509 (S) '
L510 0 FILE CIN
L511 5 S L474
PROXIMITY OPERATOR LEVEL NOT CONSISTENT WITH
FIELD CODE - 'AND' OPERATOR ASSUMED 'L511 (S) '
L512 1 FILE NLDB
L513 0 S L474
PROXIMITY OPERATOR LEVEL NOT CONSISTENT WITH
FIELD CODE - 'AND' OPERATOR ASSUMED 'L513 (S) '
L514 0 FILE CABA
L515 6 S L474
PROXIMITY OPERATOR LEVEL NOT CONSISTENT WITH
FIELD CODE - 'AND' OPERATOR ASSUMED 'L515 (S) '
L516 0 FILE PHIN
L517 0 S L474
PROXIMITY OPERATOR LEVEL NOT CONSISTENT WITH
FIELD CODE - 'AND' OPERATOR ASSUMED 'L517 (S) '
L518 0 FILE IFIPAT
L519 5 S L474
PROXIMITY OPERATOR LEVEL NOT CONSISTENT WITH
FIELD CODE - 'AND' OPERATOR ASSUMED 'L519 (S) '
L520 1 FILE ADISINSIGHT
L521 0 S L474
PROXIMITY OPERATOR LEVEL NOT CONSISTENT WITH
FIELD CODE - 'AND' OPERATOR ASSUMED 'L521 (S) '
L522 0 FILE AGRICOLA
L523 0 S L474
PROXIMITY OPERATOR LEVEL NOT CONSISTENT WITH
FIELD CODE - 'AND' OPERATOR ASSUMED 'L523 (S) '
L524 0 FILE JICST-EPLUS
L525 0 S L474
PROXIMITY OPERATOR LEVEL NOT CONSISTENT WITH
FIELD CODE - 'AND' OPERATOR ASSUMED 'L525 (S) '
L526 0 FILE EMBAL
L527 2 S L474
PROXIMITY OPERATOR LEVEL NOT CONSISTENT WITH
FIELD CODE - 'AND' OPERATOR ASSUMED 'L527 (S) '
L528 0 FILE DRUGNL
L529 3 S L474
PROXIMITY OPERATOR LEVEL NOT CONSISTENT WITH
FIELD CODE - 'AND' OPERATOR ASSUMED 'L529 (S) '
L530 0 FILE DRUGUPDATES
L531 4 S L474
PROXIMITY OPERATOR LEVEL NOT CONSISTENT WITH
FIELD CODE - 'AND' OPERATOR ASSUMED 'L531 (S) '
L532 2 FILE PHARMAML
L533 0 S L474
PROXIMITY OPERATOR LEVEL NOT CONSISTENT WITH
FIELD CODE - 'AND' OPERATOR ASSUMED 'L533 (S) '
L534 0 FILE USPAT2
L535 2 S L474
PROXIMITY OPERATOR LEVEL NOT CONSISTENT WITH
FIELD CODE - 'AND' OPERATOR ASSUMED 'L535 (S) '
L536 0 FILE ADISNEWS
L537 1 S L474
PROXIMITY OPERATOR LEVEL NOT CONSISTENT WITH
FIELD CODE - 'AND' OPERATOR ASSUMED 'L537 (S) '
L538 0 FILE BIOTECHDS
L539 1 S L474
PROXIMITY OPERATOR LEVEL NOT CONSISTENT WITH
FIELD CODE - 'AND' OPERATOR ASSUMED 'L539 (S) '
L540 0 FILE PHAR
L541 0 S L474
PROXIMITY OPERATOR LEVEL NOT CONSISTENT WITH

```
FIELD CODE - 'AND' OPERATOR ASSUMED 'L541 (S) '
L542          0 FILE AQUASCI
L543          0 S L474
PROXIMITY OPERATOR LEVEL NOT CONSISTENT WITH
FIELD CODE - 'AND' OPERATOR ASSUMED 'L543 (S) '
L544          0 FILE BIOBUSINESS
L545          1 S L474
PROXIMITY OPERATOR LEVEL NOT CONSISTENT WITH
FIELD CODE - 'AND' OPERATOR ASSUMED 'L545 (S) '
L546          0 FILE BIOCOMMERCE
L547          2 S L474
PROXIMITY OPERATOR LEVEL NOT CONSISTENT WITH
FIELD CODE - 'AND' OPERATOR ASSUMED 'L547 (S) '
L548          0 FILE FEDRIP
L549          0 S L474
PROXIMITY OPERATOR LEVEL NOT CONSISTENT WITH
FIELD CODE - 'AND' OPERATOR ASSUMED 'L549 (S) '
L550          0 FILE FROSTI
L551          0 S L474
PROXIMITY OPERATOR LEVEL NOT CONSISTENT WITH
FIELD CODE - 'AND' OPERATOR ASSUMED 'L551 (S) '
L552          0 FILE GENBANK
L553          0 S L474
PROXIMITY OPERATOR LEVEL NOT CONSISTENT WITH
FIELD CODE - 'AND' OPERATOR ASSUMED 'L553 (S) '
L554          0 FILE IPA

TOTAL FOR ALL FILES
L555         46 L474 (S) (GLUCAGON (W) SECRETION)

=> l474 and  (glucagon (w) secretion)
L474 IS NOT A RECOGNIZED COMMAND
The previous command name entered was not recognized by the system.
For a list of commands available to you in the current file, enter
"HELP COMMANDS" at an arrow prompt (=>).

=> s l474 and  (glucagon (w) secretion)
L556        396 S L474
L557          2 FILE DGENE
L558        103 S L474
L559          7 FILE BIOSIS
L560         30 S L474
L561          2 FILE CAPLUS
L562         27 S L474
L563          2 FILE SCISEARCH
L564          4 S L474
L565          0 FILE MEDLINE
L566          0 S L474
L567          0 FILE EMBASE
L568          7 S L474
L569          1 FILE ESBIOBASE
L570         34 S L474
L571          6 FILE DRUGU
L572          6 S L474
L573          0 FILE PASCAL
L574         34 S L474
L575         13 FILE USPATFULL
L576          2 S L474
L577          0 FILE TOXCENTER
L578          0 S L474
L579          0 FILE BIOTECHNO
L580         24 S L474
L581          7 FILE ADISCTI
L582         13 S L474
L583          2 FILE PROMT
```

```
L584          0 S L474
L585          0 FILE CANCERLIT
L586          7 S L474
L587          0 FILE WPIDS
L588          0 S L474
L589          0 FILE LIFESCI
L590         18 S L474
L591          0 FILE CIN
L592          5 S L474
L593          1 FILE NLDB
L594          0 S L474
L595          0 FILE CABA
L596          6 S L474
L597          0 FILE PHIN
L598          0 S L474
L599          0 FILE IFIPAT
L600          5 S L474
L601          1 FILE ADISINSIGHT
L602          0 S L474
L603          0 FILE AGRICOLA
L604          0 S L474
L605          0 FILE JICST-EPLUS
L606          0 S L474
L607          0 FILE EMBAL
L608          2 S L474
L609          0 FILE DRUGNL
L610          3 S L474
L611          0 FILE DRUGUPDATES
L612          4 S L474
L613          2 FILE PHARMAML
L614          0 S L474
L615          0 FILE USPAT2
L616          2 S L474
L617          0 FILE ADISNEWS
L618          1 S L474
L619          0 FILE BIOTECHDS
L620          1 S L474
L621          0 FILE PHAR
L622          0 S L474
L623          0 FILE AQUASCI
L624          0 S L474
L625          0 FILE BIOBUSINESS
L626          1 S L474
L627          0 FILE BIOCOMMERCE
L628          2 S L474
L629          0 FILE FEDRIP
L630          0 S L474
L631          0 FILE FROSTI
L632          0 S L474
L633          0 FILE GENBANK
L634          0 S L474
L635          0 FILE IPA

TOTAL FOR ALL FILES
L636         46 L474 AND (GLUCAGON (W) SECRETION)

=> d l636 1-46 ibib abs
NO VALID FORMATS ENTERED FOR FILE 'ADISINSIGHT'
In a multifile environment, each file must have at least one valid
format requested.  Refer to file specific help messages or the
STNGUIDE file for information on formats available in individual
files.
REENTER DISPLAY FORMAT FOR ALL FILES (FILEDEFAULT):so abs ti au

L636  ANSWER 1 OF 46  DGENE (C) 2003 THOMSON DERWENT
```

AN AAB85927 peptide DGENE
AB The invention is directed towards the amelioration of organ tissue injury caused by reperfusion of blood flow after ischemia. The method involves administering a composition containing a compound which binds to a receptor for **glucagon**-like peptide-1 (GLP-1) in a carrier. GLP-1 effectively enhances peripheral glucose uptake without inducing dangerous hypoglycemia. GLP-1 strongly suppresses **glucagon secretion**, independent of its insuliniotropic action and powerfully reduces plasma free fatty acid (FFA) level having major toxic mechanism during myocardial ischemia, substantially more than can be accomplished with insulin. The method is without side effects normally attendant with therapies presently available. GLP-1 suppresses paracrine by intra-islet release of insulin or somatostatin. GLP-1 is unique in its capacity to simultaneously stimulate insulin secretion and inhibit **glucagon** release. The present sequence represents a gila monster venom **exendin 4** peptide fragment, homologous to a mammalian GLP-1 peptide fragment.
TI Use of **glucagon**-like peptide-one for amelioration of organ tissue e.g. myocardium, injury after ischemia -
IN Coolidge T R; Ehlers M R W

L636 ANSWER 2 OF 46 DGENE (C) 2003 THOMSON DERWENT
AN AAB85926 peptide DGENE
AB The invention is directed towards the amelioration of organ tissue injury caused by reperfusion of blood flow after ischemia. The method involves administering a composition containing a compound which binds to a receptor for **glucagon**-like peptide-1 (GLP-1) in a carrier. GLP-1 effectively enhances peripheral glucose uptake without inducing dangerous hypoglycemia. GLP-1 strongly suppresses **glucagon secretion**, independent of its insuliniotropic action and powerfully reduces plasma free fatty acid (FFA) level having major toxic mechanism during myocardial ischemia, substantially more than can be accomplished with insulin. The method is without side effects normally attendant with therapies presently available. GLP-1 suppresses paracrine by intra-islet release of insulin or somatostatin. GLP-1 is unique in its capacity to simultaneously stimulate insulin secretion and inhibit **glucagon** release. The present sequence represents a gila monster venom **exendin 4** peptide fragment, homologous to a mammalian GLP-1 peptide fragment.
TI Use of **glucagon**-like peptide-one for amelioration of organ tissue e.g. myocardium, injury after ischemia -
IN Coolidge T R; Ehlers M R W

L636 ANSWER 3 OF 46 BIOSIS COPYRIGHT 2003 BIOLOGICAL ABSTRACTS INC.
SO Biomedical Research (Tokyo), (December, 2002) Vol. 22, No. 6, pp. 295-297. print.
ISSN: 0388-6107.
AB **Glucagon**-like peptide-1 (GLP-1) is known to lower blood glucose level, the effect depending on the stimulation of insulin and the inhibition of **glucagon secretion**. Due to the rapid inactivation of GLP-1 by dipeptidyl peptidase-IV (DPP-IV), its biological action is very short. Hence, we investigated the effect on rat entero-insular axis of **exendin-4**, a DPP-IV-resistant agonist of GPL-1 receptors. As expected the bolus administration of **exendin-4** (12 nmol/kg) increased the plasma concentration of insulin and decreased the blood levels of both **glucagon** and leptin in normal rats; however, GLP-1 raised glycemia. **Exendin-4** did not evoke any effect in rats bearing enucleated-regenerated adrenals deprived of medullary tissue, thereby suggesting that its stimulating effect of entero-insular axis occurs via an indirect mechanism probably involving medullary catecholamines. Catecholamines are potent stimulator of hepatic glycogenolysis, and this may tentatively explain the hyperglycemizing effect of **exendin-4**.
TI **Exendin-4**, a GLP-1 receptor agonist, stimulates

entero-insular axis in the rat, through a mechanism involving adrenal medulla.
AU Malendowicz, Ludwik K.; Nowak, Krzysztof W.; Zyterska, Agnieszka; Nussdorfer, Gastone G. (1); Macchi, Carlo; Nowak, Magdalena

L636 ANSWER 4 OF 46 BIOSIS COPYRIGHT 2003 BIOLOGICAL ABSTRACTS INC.
SO Diabetes, (June, 2001) Vol. 50, No. Supplement 2, pp. A313. print.
Meeting Info.: 61st Scientific Sessions of the American Diabetes Association Philadelphia, Pennsylvania, USA June 22-26, 2001.
ISSN: 0012-1797.
TI Effect of **exendin-4** on **glucagon secretion** in lean and obese Zucker (ZDF) rats.
AU Parkes, David (1); Gedulin, Bronislava (1); Smith, Pamela (1); Young, Andrew (1)

L636 ANSWER 5 OF 46 BIOSIS COPYRIGHT 2003 BIOLOGICAL ABSTRACTS INC.
SO Experimental and Clinical Endocrinology & Diabetes, (2001) Vol. 109, No. Suppl. 2, pp. S288-S303. print.
ISSN: 0947-7349.
AB The search for intestinal factors regulating the endocrine secretion of the pancreas started soon after the discovery of secretin, i.e. nearly 100 years ago. Insulinotropic factors of the gut released by nutrients and stimulating insulin secretion in physiological concentrations in the presence of elevated blood glucose levels have been named incretins. Of the known gut hormones only gastric inhibitory polypeptide (GIP) and **glucagon**-like polypeptide-1 (GLP-1 (7-36) amide) fulfill this definition. - The incretin effect (i.e. the ratio between the integrated insulin response to an oral glucose load and an isoglycaemic intravenous glucose infusion) is markedly diminished in patients with type 2 diabetes mellitus, while the plasma levels of GIP and GLP-1 and their responses to nutrients are in the normal range. Therefore, a reduced responsiveness of the islet B-cells to incretins has been postulated. This insensitivity of the diabetic B-cells towards incretins can be overcome by supraphysiological (pharmacological) concentrations of GLP-1 (7-36), however not of GIP. Accordingly, fasting and postprandial glucose levels can be normalized in patients with type 2 diabetes by infusions of GLP-1 (7-36). Further studies revieled that this is partially due to the fact that GLP-1 (7-36) - in addition to its insulinotropic effect - also inhibits **glucagon secretion** and delays gastric emptying. These three antidiabetic effects qualify GLP-1 (7-36) as an interesting therapeutic tool, mainly for type 2 diabetes. However, because of its short plasma half life time natural GLP-1 (7-36) is not suitable for subcutaneous application. At present methods are being developed to improve the pharmacokinetics of GLP-1 by inhibition of the cleaving enzyme dipeptidyl peptidase IV (DPP-IV) or by synthesis of DPP-IV resistant GLP-1 analogues. Also naturally occurring GLP-1 analogues (for instance **exendin-4**) with a much longer half life time than GLP-1 (7-36) are being tested. - Thus, after 100 years of speculations and experimentations, incretins and their analogues are emerging as new antidiabetic drugs.
TI The entero-insular axis in type 2 diabetes - incretins as therapeutic agents.
AU Creutzfeldt, W. (1)

L636 ANSWER 6 OF 46 BIOSIS COPYRIGHT 2003 BIOLOGICAL ABSTRACTS INC.
SO European Journal of Endocrinology, (December, 2000) Vol. 143, No. 6, pp. 717-725. print.
ISSN: 0804-4643.
AB **Glucagon**-like peptide-1 (GLP-1) is a gut hormone synthesized by post-translational processing in intestinal L-cells, and it is released in response to food ingestion. GLP-1 stimulates insulin secretion during hyperglycemia, suppresses **glucagon secretion**, stimulates (pro)-insulin biosynthesis and decreases the rate of gastric emptying and acid secretion. GLP-1 has also been shown to have a pro-satiety effect. In addition, it has been demonstrated that a long-term

infusion with GLP-1, or **exendin-4**, a long-acting analog of human GLP-1, increases beta-cell mass in rats. In conclusion, GLP-1 appears to regulate plasma glucose levels via various and independent mechanisms. GLP-1 is an excellent candidate option for the treatment of patients with type 2 diabetes mellitus.

TI **Glucagon**-like peptide-1: A major regulator of pancreatic beta-cell function.

AU Perfetti, Riccardo (1); Merkel, Patricia

L636 ANSWER 7 OF 46 BIOSIS COPYRIGHT 2003 BIOLOGICAL ABSTRACTS INC.

SO Diabetes, (1999) Vol. 48, No. SUPPL. 1, pp. A198.
Meeting Info.: 59th Scientific Sessions of the American Diabetes Association San Diego, California, USA June 19-22, 1999 American Diabetes Association
. ISSN: 0012-1797.

TI **Exendin-4** (AC2993) decreases **glucagon secretion** during hyperglycemic clamps in Diabetic Fatty Zucker rats.

AU Gedulin, Bronislava (1); Jodka, Lynne (1); Hoyt, Julie (1)

L636 ANSWER 8 OF 46 BIOSIS COPYRIGHT 2003 BIOLOGICAL ABSTRACTS INC.

SO Diabetes, (Feb., 1998) Vol. 47, No. 2, pp. 159-169.
ISSN: 0012-1797.

AB Proglucagon contains the sequence of two **glucagon**-like peptides, GLP-1 and GLP-2, secreted from enteroendocrine cells of the small and large intestine. GLP-1 lowers blood glucose in both NIDDM and IDDM patients and may be therapeutically useful for treatment of patients with diabetes. GLP-1 regulates blood glucose via stimulation of glucose-dependent insulin secretion, inhibition of gastric emptying, and inhibition of **glucagon secretion**. GLP-1 may also regulate glycogen synthesis in adipose tissue and muscle; however, the mechanism for these peripheral effects remains unclear. GLP-1 is produced in the brain, and intracerebroventricular GLP-1 in rodents is a potent inhibitor of food and water intake. The short duration of action of GLP-1 may be accounted for in part by the enzyme dipeptidyl peptidase 4 (DPP-IV), which cleaves GLP-1 at the NH2-terminus; hence GLP-1 analogs or the lizard peptide **exendin-4** that are resistant to DPP-IV cleavage may be more potent GLP-1 molecules in vivo. GLP-2 has recently been shown to display intestinal growth factor activity in rodents, raising the possibility that GLP-2 may be therapeutically useful for enhancement of mucosal regeneration in patients with intestinal disease. This review discusses recent advances in our understanding of the biological activity of the **glucagon**-like peptides.

TI **Glucagon**-like peptides.

AU Drucker, Daniel J. (1)

L636 ANSWER 9 OF 46 BIOSIS COPYRIGHT 2003 BIOLOGICAL ABSTRACTS INC.

SO Journal of Biological Chemistry, (1997) Vol. 272, No. 7, pp. 4108-4115.
ISSN: 0021-9258.

AB **Glucagon**-like peptide 1 stimulates insulin secretion and inhibits **glucagon secretion**, gastric emptying, and feeding, suggesting it may be biologically useful for the treatment of diabetes. A lizard **glucagon**-like peptide 1 (GLP-1)-related peptide, **exendin 4**, binds to the GLP-1 receptor and mimics the actions of GLP-1 in vivo. To determine the genetic relationship between **exendin 4** and GLP-1, we analyzed the structure and expression of pancreatic and intestinal proglucagon mRNAs in the reptile Heloderma suspectum. Two different proglucagon cDNAs (lizard proglucagon I (LPI) and lizard proglucagon II (LPII)), with unique 3'-untranslated regions were identified. Two LPI mRNA transcripts, apprx 1.6 and 2.1 kilobases, encoded **glucagon** and GLP-1 but not GLP-2 and were restricted in expression to the pancreas. In contrast, a 1.1-kilobase LPII mRNA transcript, encoding **glucagon**, GLP-1, and GLP-2 utilized a different 3'-untranslated region and was expressed in both pancreas and intestine. Lizard proglucagon mRNA transcripts were not

detectable by reverse transcription-polymerase chain reaction or Northern blotting in salivary gland. A single class of lizard salivary gland proexendin cDNAs encoded the sequence of **exendin 4** and a 45-amino acid **exendin** NH-2-terminal peptide. **Exendin** mRNA transcripts were expressed in the salivary gland, but not pancreas or intestine. These data demonstrate that GLP-1 and **exendin 4** represent related yet distinct peptides encoded by different genes in the lizard.

TI Tissue-specific expression of unique mRNAs that encode proglucagon-derived peptides or **exendin 4** in the lizard.

AU Chen, Yuqing E.; Drucker, Daniel J. (1)

L636 ANSWER 10 OF 46 CAPLUS COPYRIGHT 2003 ACS

SO Biomedical Research (2001), 22(6), 295-297
CODEN: BRESD5; ISSN: 0388-6107

AB **Glucagon**-like peptide-1 (GLP-1) is known to lower blood glucose level, the effect depending on the stimulation of insulin and the inhibition of **glucagon secretion**. Due to the rapid inactivation of GLP-1 by dipeptidyl peptidase-IV (DPP-IV), its biol. action is very short. Hence, we investigated the effect on rat entero-insular axis of **Exendin-4**, a DPP-IV-resistant agonist of GPL-1 receptors. As expected the bolus administration of **Exendin-4** (12 nmol/kg) increased the plasma concn. of insulin and decreased the blood levels of both **glucagon** and leptin in normal rats; however, GLP-1 raised glycemia. **Exendin-4** did not evoke any effect in rats bearing enucleated-regenerated adrenals deprived of medullary tissue, thereby suggesting that its stimulating effect of entero-insular axis occurs via an indirect mechanism probably involving medullary catecholamines. Catecholamines are potent stimulator of hepatic glycogenolysis, and this may tentatively explain the hyperglycemizing effect of **Exendin-4**.

TI **Exendin-4**, a GLP-1 receptor agonist, stimulates entero-insular axis in the rat, through a mechanism involving adrenal medulla

AU Malendowicz, Ludwik K.; Nowak, Krzysztof W.; Zyterska, Agnieszka; Nussdorfer, Gastone G.; Macchi, Carlo; Nowak, Magdalena

L636 ANSWER 11 OF 46 CAPLUS COPYRIGHT 2003 ACS

SO PCT Int. Appl., 96 pp.
CODEN: PIXXD2

AB Methods are provided for use of an **exendin**, an **exendin** agonist, or a modified **exendin** or **exendin** agonist having an **exendin** or **exendin** agonist linked to one or more polyethylene glycol polymers, for example, for lowering **glucagon** levels and/or suppressing **glucagon secretion** in a subject. These methods are useful in treating hyperglucagonemia and other conditions that would be benefited by lowering plasma **glucagon** or suppressing **glucagon secretion**.

TI Methods using an **exendin** or related substance for **glucagon** suppression

IN Young, Andrew; Gedulin, Bronislava

L636 ANSWER 12 OF 46 SCISEARCH COPYRIGHT 2003 ISI (R)

SO DIABETES, (MAY 2000) Vol. 49, Supp. [1], pp. 460-460.
Publisher: AMER DIABETES ASSOC, 1660 DUKE ST, ALEXANDRIA, VA 22314.
ISSN: 0012-1797.

TI Dose-response for inhibition of **glucagon secretion** and gastric emptying by synthetic **exendin-4** (AC2993) in subjects with type 2 diabetes

AU Kolterman O (Reprint); Gottlieb A; Prickett K; Gaines E; Young A

L636 ANSWER 13 OF 46 SCISEARCH COPYRIGHT 2003 ISI (R)

SO DIABETES, (JUN 1999) Vol. 48, Supp. [1], pp. 864-864.
Publisher: AMER DIABETES ASSOC, 1660 DUKE ST, ALEXANDRIA, VA 22314.

ISSN: 0012-1797.

TI **Exendin-4** (AC2993) decreases **glucagon secretion** during hyperglycemic clamps in Diabetic Fatty Zucker rats

AU Gedulin B (Reprint); Jodka L; Hoyt J

L636 ANSWER 14 OF 46 Elsevier BIOBASE COPYRIGHT 2003 Elsevier Science B.V.

SO Experimental and Clinical Endocrinology and Diabetes, (2001), 109/SUPPL. 2 (S288-S303), 122 reference(s)
CODEN: ECEDFQ ISSN: 0947-7349

AB The search for intestinal factors regulating the endocrine secretion of the pancreas started soon after the discovery of secretin, i.e. nearly 100 years ago. Insulinotropic factors of the gut released by nutrients and stimulating insulin secretion in physiological concentrations in the presence of elevated blood glucose levels have been named incretins. Of the known gut hormones only gastric inhibitory polypeptide (GIP) and **glucagon**-like polypeptide-1 (GLP-1 [7 - 36] amide) fulfill this definition. - The incretin effect (i.e. the ratio between the integrated insulin response to an oral glucose load and an isoglycaemic intravenous glucose infusion) is markedly diminished in patients with type 2 diabetes mellitus, while the plasma levels of GIP and GLP-1 and their responses to nutrients are in the normal range. Therefore, a reduced responsiveness of the islet B-cells to incretins has been postulated. This insensitivity of the diabetic B-cells towards incretins can be overcome by supraphysiological (pharmacological) concentrations of GLP-1 [7 - 36], however not of GIP. Accordingly, fasting and postprandial glucose levels can be normalized in patients with type 2 diabetes by infusions of GLP-1 [7 - 36]. Further studies revieled that this is partially due to the fact that GLP-1 [7 - 36] - in addition to its insulinotropic effect - also inhibits **glucagon secretion** and delays gastric emptying. These three antidiabetic effects qualify GLP-1 [7 - 36] as an interesting therapeutic tool, mainly for type 2 diabetes. However, because of its short plasma half life time natural GLP-1 [7 - 36] is not suitable for subcutaneous application. At present methods are being developed to improve the pharmacokinetics of GLP-1 by inhibition of the cleaving enzyme dipeptidyl peptidase IV (DPP-IV) or by synthesis of DPP-IV resistant GLP-1 analogues. Also naturally occurring GLP-1 analogues (for instance **exendin-4**) with a much longer half life time than GLP-1 [7 - 36] are being tested. - Thus, after 100 years of speculations and experimentations, incretins and their analogues are emerging as new antidiabetic drugs.

TI The entero-insular axis in type 2 diabetes - Incretins as therapeutic agents

AU Creutzfeldt W.

L636 ANSWER 15 OF 46 DRUGU COPYRIGHT 2003 THOMSON DERWENT

SO Diabetologia (45, Suppl. 2, A214, 2002)
CODEN: DBTGAJ ISSN: 0012-186X

AV Department of Physiology, Clinica Puerta de Hierro, Universidad Autonoma de Madrid, Madrid, Spain.

AN 2002-37701 DRUGU P E

AB In-vitro, **exendin-4** (Amylin) directly inhibited alpha-cell secretion in perfused rat pancreas. **Exendin-4** is an insulinotropic peptide structurally analogous to GLP-1. (conference abstract: 38th Annual Meeting of the European Association for the Study of Diabetes, Budapest, Hungary, 2002).

ABEX **Exendin-4** (1 nM) appreciably potentiated insulin and somatostatin responses to arginine (10 mM) and appreciably reduced **glucagon** response to this aminoacid by about 3x. **Exendin-4** (1 nM) appreciably reduced the increase in **glucagon secretion** induced by abrupt glucose depletion (from 11 to 3.2 mM) but had no effect on the dramatic decrease in insulin release or the slight decrease in somatostatin release under these conditions. (E42/JM)

TI Evidence for a direct inhibitory effect of **exendin-4** on alpha cell secretion.

AU Rodriguez Gallardo J; Egido E M; Gutierrez E; Garcia P; Silvestre R A; Marco J

L636 ANSWER 16 OF 46 DRUGU COPYRIGHT 2003 THOMSON DERWENT
SO Diabetes (51, Suppl. 2, A339-A340, 2002)
CODEN: DIAEAZ ISSN: 0012-1797
AV No Reprint Address.
AN 2002-31847 DRUGU P E
AB The effects of **exendin-4** and **glucagon**-like peptide (GLP)-1 were compared in isolated perfused pig pancreas preparations. Both peptides slightly reduced vascular resistance but neither affected pancreas exocrine excretion. Both peptides stimulated insulin (up to 203% and 309% respectively) and somatostatin (208% and 105%) at 0.01-10 nM and both inhibited **glucagon secretion**. It is concluded that **exendin-4** and GLP-1 have identical endocrine effects and similar potency in the pig pancreas. (conference abstract: 62nd Scientific Sessions of the American Diabetes Association, San Francisco, California, USA, 2002). (No EX).
ABEX (E33/JB)
TI **Exendin-4** and **glucagon**-like peptide-1 have similar effects in isolated perfused porcine pancreas.
AU Hansen L; Nielsen J Z; Holst J J

L636 ANSWER 17 OF 46 DRUGU COPYRIGHT 2003 THOMSON DERWENT
SO Diabetes (50, Suppl. 2, A313, 2001)
CODEN: DIAEAZ ISSN: 0012-1797
AV No reprint address.
AN 2002-03605 DRUGU P E
AB The effect of i.v. **exendin-4** on **glucagon** synthesis was investigated in a rat model of type 2 diabetes. **Exendin-4** suppressed **glucagon secretion** in lean and obese diabetic Zucker rats via a mechanism distinct from elevation of plasma glucose. The results support the use of **exendin-4** in diabetic conditions where excessive **glucagon secretion** contributes to fasting hyperglycemia. (conference abstract: 61st Scientific Sessions of the American Diabetes Association, Philadelphia, Pennsylvania, USA, 2001).
ABEX Methods Lean and obese (diabetic) Zucker rats were administered i.v. **exendin-4** (2.6 ug/hr) or saline for 30 min. Results In obese rats treated with **exendin-4**, **glucagon** decreased from 94 to 54 pM despite a decrease in plasma glucose. In lean rats, **exendin-4** decreased **glucagon** from 61 to 44 pM at 30 min accompanied by a decrease in plasma glucose. (E97)
TI Effect of **exendin-4** on **glucagon** synthesis in lean and obese Zucker (ZDF) rats.
AU Parkes D; Gedulin B; Smith P; Young A

L636 ANSWER 18 OF 46 DRUGU COPYRIGHT 2003 THOMSON DERWENT
SO Exp.Clin.Endocrinol.Diabetes (109, Suppl. 2, S288-S203, 2001) 2 Fig. 1 Tab. 122 Ref.
CODEN: ECEDF ISSN: 0947-7349
AV Zentrum Innere Medizin, Klinikum der Universitaet, Robert- Koch-Str. 40 D-37075 Goettingen, Germany.
AN 2001-26811 DRUGU T E
AB Incretins as therapeutics agents for type 2 diabetes is reviewed with specific reference to **glucagon**-like polypeptide-1 (GLP-1 [7-36] amide).
ABEX Insulinotropic factors of the gut release by nutrients and stimulating insulin secretion in physiological concentrations in the presence of elevated blood glucose levels had been named incretins. Of the known gut hormones only gastric inhibitory polypeptide (GIP) and **glucagon**-like polypeptide-1 (GLP-1 [7-36] amide) fulfill this definition. The incretin effect (i.e. the ratio between the integrated insulin response to an oral glucose load and an isoglycemic i.v. glucose infusion) is

markedly diminished in patients with type 2 diabetes mellitus, while the plasma levels of GIP and GLP-1 and their response to nutrients are in the normal range. Therefore a reduced responsiveness to the islet B cells to incretins has been postulated, This insensitivity of the diabetic B-cells towards incretins can be overcome by supraphysiological concentrations of GLP-1 [7-36], however not of GIP. Accordingly, fasting and postprandial glucose levels can be normalized in patients with type 2 diabetes by infusions of GLP-1 [7-36]. GLP-1 [7-36] also inhibits **glucagon secretion** and delays gastric emptying. Because of its short plasma half-life time natural GLP-1 [7-36] is not suitable for s.c. application. Naturally occurring GLP-1 analogs (e.g. **exendin-4**) with a much longer half-life time than GLP-1 [7-36] are being tested. (E98)

TI The entero-insular axis in type 2 diabetes - incretins as therapeutic agents.

AU Creutzfeldt W

L636 ANSWER 19 OF 46 DRUGU COPYRIGHT 2003 THOMSON DERWENT

SO Diabetes (49, Suppl. 1, A114, 2000)
CODEN: DIAEAZ ISSN: 0012-1797

AV No Reprint Address.

AN 2000-40616 DRUGU T E

AB S.c. synthetic **exendin-4** (AC-2993) inhibited postprandial plasma glucose and **glucagon** elevations and gastric emptying in 14 patients with type-2 diabetes. Each of these effects demonstrated similar dose potency. (conference abstract: 60th Scientific Sessions of the American Diabetes Association, San Antonio, Texas, USA, 2000).

ABEX Methods Patients (mean age 55 yr) received single injections of AC-2993 (0.01, 0.02, 0.05 or 0.1 ug/kg) or placebo on separate days following an overnight fast. Injections were given immediately prior to ingestion of a standard Sustacal meal (7 kcal/kg). Gastric emptying was evaluated by giving liquid phenazone (20 mg/kg) along with the meal and monitoring phenazone appearance in plasma. Results AC-2993 inhibited postprandial glucose and **glucagon** elevations and gastric-emptying in a dose-dependent manner with ED50 values of 0.038, 0.017 and 0.048 ug/kg, respectively. (E42/JM)

TI Dose-response for inhibition of **glucagon secretion** and gastric emptying by synthetic **exendin-4** (AC2993) in subjects with type 2 diabetes.

AU Kolterman O; Gottlieb A; Prickett K; Gaines E; Young A

L636 ANSWER 20 OF 46 DRUGU COPYRIGHT 2003 THOMSON DERWENT

SO Diabetes (48, Suppl. 1, A199, 1999)
CODEN: DIAEAZ ISSN: 0012-1797

AV No Reprint Address.

AN 1999-28905 DRUGU P E

AB Effects of i.v. infusion of **exendin-4** (AC-2993), a 39 amino acid peptide isolated from salivary secretions of the Gila monster (Heloderma suspectum), with antidiabetic actions similar to those of GLP-1, on **glucagon secretion** were investigated in anesthetized male diabetic fatty Zucker (ZDF) rats. **Exendin-4** exhibited a glucagonostatic effect in ZDF rats during hyperglycemic clamp studies, an effect which if present in diabetic humans, could be of potential therapeutic benefit. (conference abstract: 59th Annual Scientific Sessions of the American Diabetes Association, San Diego, California, USA, 1999).

ABEX Using an hyperinsulinemic hyperglycemic clamp protocol, those factors tending to influence **glucagon secretion** were held constant. Plasma glucose was clamped at about 34 mM 60 min before beginning infusions of saline or **exendin-4** (0.21 +/- 2.1 ug/ml/hr). Plasma **glucagon** concentration measured prior to these infusions were similar in both groups (306 vs. 252 pM, respectively). Mean plasma **glucagon** concentration in **exendin-4** infused rats was nearly half of that in

saline-infused rats in the final 60 min of the clamp (165 vs. 2984 pM, respectively). The hyperglycemic clamp protocol also enabled the measurement of insulin sensitivity. Glucose infusion rate during the clamp was increased by 111% in **exendin-4**-treated vs. control rats. (E54/RSV)

TI **Exendin-4** (AC2993) decreases **glucagon-secretion** during hyperglycemic clamps in diabetic fatty Zucker rats.

AU Gedulin B; Jodka L; Hoyt J

L636 ANSWER 21 OF 46 USPATFULL

AB Methods for treating gestational diabetes which comprise administration of an effective amount of an exendin or an exendin agonist, alone or in conjunction with other compounds or compositions that lower blood glucose levels.

TI Use of exendins and agonists thereof for the treatment of gestational diabetes mellitus

IN Hiles, Richard A., San Diego, CA, United States
Prickett, Kathryn S., San Diego, CA, United States

L636 ANSWER 22 OF 46 USPATFULL

AB Dipeptidyl peptidase IV (DP 4) inhibiting compounds are provided having the formula ##STR1##

where n is 0 or 1; X is H or CN;

Y is N, NH or 0;

Z is CH.sub.2 when Y is 0 or N--H, with Y--Z forming a single bond, and Z is CH when Y is N, with Y--Z forming a double bond;

and wherein R.sup.1, R.sup.2, R.sup.3 and R.sup.4 are as described herein.

A method is also provided for treating diabetes and related diseases, especially Type II diabetes, and other diseases as set out herein, employing such DP 4 inhibitor or a combination of such DP 4 inhibitor and one or more of another antidiabetic agent such as metformin, glyburide, troglitazone, pioglitazone, rosiglitazone and/or insulin and/or one or more of a hypolipidemic agent and/or anti-obesity agent and/or other therapeutic agent.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

TI 2,1-Oxazoline and 1,2-pyrazoline-based inhibitors of dipeptidyl peptidase IV and method

IN Sulsky, Richard B., West Trenton, NJ, UNITED STATES
Robl, Jeffrey A., Newtown, PA, UNITED STATES

L636 ANSWER 23 OF 46 USPATFULL

AB Individuals in need of treatment of ischemia-related reperfusion are treated, preferably intravenously, with a composition which includes a compound which binds to a receptor for the **glucagon**-like peptide-1. The invention relates to both the method and compositions for such treatment.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

TI Metabolic intervention with GLP-1 to improve the function of ischemic and reperfused skeletal muscle tissue

IN Coolidge, Thomas R., Falls Village, CT, UNITED STATES
Ehlers, Mario R.W., Lincoln, NE, UNITED STATES

L636 ANSWER 24 OF 46 USPATFULL

AB Methods for treating conditions or disorders which can be alleviated by reducing food intake are disclosed which comprise administration of an

effective amount of an exendin or an exendin agonist, alone or in conjunction with other compounds or compositions that affect satiety. The methods are useful for treating conditions or disorders, including obesity, Type II diabetes, eating disorders, and insulin-resistance syndrome. The methods are also useful for lowering the plasma glucose level, lowering the plasma lipid level, reducing the cardiac risk, reducing the appetite, and reducing the weight of subjects. Pharmaceutical compositions for use in the methods of the invention are also disclosed.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.
TI USE OF EXENDINS AND AGONISTS THEREOF FOR THE REDUCTION OF FOOD INTAKE
IN BEELEY, NIGEL ROBERT ARNOLD, SOLANA BEACH, CA, UNITED STATES
PRICKETT, KATHRYN S., SAN DIEGO, CA, UNITED STATES
BHAVSAR, SUNIL, SAN DIEGO, CA, UNITED STATES

L636 ANSWER 25 OF 46 USPATFULL
AB The effects of GLP-2 are enhanced using a GLP-1 activity inhibitor. For medical use to treat or inhibit the onset of medical conditions, disorder or diseases for which treatment with GLP-2 is indicated, the present invention provides a pharmaceutical combination comprising a GLP-2 activity enhancer, and a GLP-1 activity inhibitor. The combination is useful particularly to treat gastrointestinal conditions such as small bowel syndrome, mucositis and Crohn's disease, and to suppress appetite, for instance to treat obesity.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.
TI Enhancement of GLP-2 activity
IN Drucker, Daniel J., Toronto, CANADA
Lovshin, Julie Ann Louise, Toronto, CANADA

L636 ANSWER 26 OF 46 USPATFULL
AB Individuals in need of treatment of ischemia-related reperfusion are treated, preferably intravenously, with a composition which includes a compound which binds to a receptor for the **glucagon**-like peptide-1. The invention relates to both the method and compositions for such treatment.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.
TI Metabolic intervention with GLP-1 to improve the function of ischemic and reperfused tissue
IN Coolidge, Thomas R., Falls Village, CT, UNITED STATES
Ehlers, Mario R.W., Lincoln, NE, UNITED STATES

L636 ANSWER 27 OF 46 USPATFULL
AB Modified insulinotropic peptides are disclosed. The modified insulinotropic peptides are capable of forming a peptidase stabilized insulinotropic peptide. The modified insulinotropic peptides are capable of forming covalent bonds with one or more blood components to form a conjugate. The conjugates may be formed in vivo or ex vivo. The modified peptides are administered to treat humans with diabetes and other related diseases.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.
TI Long lasting insulinoptropic peptides
IN Bridon, Dominique P., Outremont, CANADA
L'Archeveque, Benoit, Leval, CANADA
Ezrin, Alan M., Moraga, CA, UNITED STATES
Holmes, Darren L., Montreal, CANADA
Leblanc, Anouk, Montreal, CANADA
St. Pierre, Serge, Ile Bizard, CANADA

L636 ANSWER 28 OF 46 USPATFULL
AB Compositions and methods using same for the treatment of diabetes its sequelae and pre-diabetic conditions are provided. Invention

compositions include the anti-diabetic agent metformin, and bioavailable sources of one or more of chromium, vanadium and magnesium. Also provided are pharmaceutical agents containing invention compositions and methods for administering such agents.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.
TI Metforimin-containing compositions for the treatment of diabetes
IN Fine, Stuart A., Northbrook, IL, United States
Kinsella, Kevin J., La Jolla, CA, United States

L636 ANSWER 29 OF 46 USPATFULL
AB Dipeptidyl peptidase IV (DP 4) inhibiting compounds are provided having the formula ##STR1##

where x is 0 or 1 and y is 0 or 1 (provided that x=1 when y=0 and x=0 when y=1);

n is 0 or 1; X is H or CN;

and wherein R.sup.1, R.sup.2, R.sup.3 and R.sup.4 are as described herein.

A method is also provided for treating diabetes and related diseases, especially Type II diabetes, and other diseases as set out herein, employing such DP 4 inhibitor or a combination of such DP 4 inhibitor and one or more of another antidiabetic agent such as metformin, glyburide, troglitazone, pioglitazone, rosiglitazone and/or insulin and/or one or more of a hypolipidemic agent and/or anti-obesity agent and/or other therapeutic agent.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.
TI Cyclopropyl-fused pyrrolidine-based inhibitors of dipeptidyl peptidase IV and method
IN Robl, Jeffrey A., Newtown, PA, UNITED STATES
Sulsky, Richard B., West Trenton, NJ, UNITED STATES
Augeri, David J., Princeton, NJ, UNITED STATES
Magnin, David R., Hamilton, NJ, UNITED STATES
Hamann, Lawrence G., Cherry Hill, NJ, UNITED STATES
Betebenner, David A., Lawrenceville, NJ, UNITED STATES

L636 ANSWER 30 OF 46 USPATFULL
AB Since **glucagon**-like peptide-1 (GLP-1) is the most potent insulinotropic hormone known and has been shown to stimulate insulin secretion strongly in patients with type II diabetes, this invention uses GLP-1 or its biologically active analogues in .beta.-cell stimulatory tests in order to test .beta.-cell function in a simple way. The test provides information about insulin secretory capacity, is easy and reproducible and has insignificant side effects.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.
TI GLP-1 as a diagnostic test to determine .beta.-cell function and the presence of the condition of IGT and type II diabetes
IN Holst, J. J., Copenhagen, DENMARK
Vilsboll, Tina, Hellerup, DENMARK

L636 ANSWER 31 OF 46 USPATFULL
AB Modified insulinotropic peptides are disclosed. The modified insulinotropic peptides are capable of forming a peptidase stabilized insulinotropic peptide. The modified insulinotropic peptides are capable of forming covalent bonds with one or more blood components to form a conjugate. The conjugates may be formed in vivo or ex vivo. The modified peptides are administered to treat humans with diabetes and other related diseases.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

TI Long lasting insulinotropic peptides
IN Bridon, Dominique P., Outremont, Canada
L'Archeveque, Benoit, Laval, Canada
Ezrin, Alan M., Moraga, CA, United States
Holmes, Darren L., Montreal, Canada
Leblanc, Anouk, Montreal, Canada
St. Pierre, Serge, Ile Bizard, Canada

L636 ANSWER 32 OF 46 USPATFULL
AB The present invention relates to a derivative of GLP-1 (7-C), wherein C is 35 or 36 which derivative has just one lipophilic substituent which is attached to the C-terminal amino acid residue.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.
TI Extendin derivatives
IN Knudsen, Liselotte Bjerre, Valby, Denmark
Huusfeldt, Per Olaf, Copenhagen K, Denmark
Nielsen, Per Franklin, Vaerlose, Denmark
Madsen, Kjeld, Vaerlose, Denmark

L636 ANSWER 33 OF 46 USPATFULL
AB Individuals in need of treatment of ischemia-related reperfusion are treated, preferably intravenously, with a composition which includes a compound which binds to a receptor for the **glucagon**-like peptide-1. The invention relates to both the method and compositions for such treatment.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.
TI Metabolic intervention with GLP-1 to improve the function of ischemic and reperfused tissue
IN Coolidge, Thomas R., Falls Village, CT, United States
Ehlers, Mario R. W., Lincoln, NE, United States

L636 ANSWER 34 OF 46 ADISCTI COPYRIGHT 2003 (ADIS)
SO Diabetologia (Oct 1, 2002), Vol. 45, pp. 1410-1415
TI Lack of effect of **exendin-4** and **glucagon**
-like peptide-1-(7,36)-amide on insulin action in non-diabetic humans.
ADIS TITLE: **Exendin 4**, **glucagon**-like
peptide-1 (7,36) amide: pharmacodynamics.
Effects on insulin action
In volunteers.
AU Vella A; Shah P; Reed A S; Adkins A S; Basu R; et al.

L636 ANSWER 35 OF 46 ADISCTI COPYRIGHT 2003 (ADIS)
SO Diabetologia (Aug 1, 2002), Vol. 45 (Suppl. 2), pp. 44
TI 28 days of treatment with AC2993 (synthetic **exendin-4**)
improved glycemic control in patients with type 2 diabetes concomitantly treated with metformin and sulfonylurea.
ADIS TITLE: **Exendin 4**: therapeutic use.
Type 2 diabetes mellitus
In obese patients receiving metformin and/or sulphonylureas.
AU Fineman M; Bicsak T; Shen L; Taylor K; Gaines E; et al.

L636 ANSWER 36 OF 46 ADISCTI COPYRIGHT 2003 (ADIS)
SO Diabetes (Jun 1, 2002), Vol. 51 (Suppl. 2), pp. 104 (plus poster)
TI Subcutaneous injection of AC2993 (synthetic **exendin-4**)
lowered fasting glucose concentrations through suppression of **glucagon** and dose dependent insulinotropism in patients with type 2 diabetes.
ADIS TITLE: **Exendin 4**: pharmacodynamics.
Effects on fasting plasma glucose, serum insulin and plasma **glucagon** levels
In patients with type 2 diabetes mellitus receiving metformin and/or thiazolidinediones.
AU Kim D; Taylor K; Bicsak T; Wang Y; Aisporna M; et al.

L636 ANSWER 37 OF 46 ADISCTI COPYRIGHT 2003 (ADIS)
SO Diabetes (Jun 1, 2002), Vol. 51 (Suppl. 2), pp. 84-85
TI **Exendin-4** reduces glycemic excursions after meals in insulin-treated diabetes.
ADIS TITLE: **Exendin 4**: pharmacodynamics.
Effects on postprandial gastric emptying
In patients with type 1 diabetes mellitus receiving insulin.
AU Dupre J; Behme M T; McDonald T J.

L636 ANSWER 38 OF 46 ADISCTI COPYRIGHT 2003 (ADIS)
SO Diabetes (May 1, 2000), Vol. 49 (Suppl. 1), pp. 114 (plus poster)
TI Dose-response for inhibition of **glucagon secretion** and gastric emptying by synthetic **exendin-4** (AC2993) in subjects with type 2 diabetes.
ADIS TITLE: **Exendin-4**: pharmacodynamics.
Effects on **glucagon secretion** and gastric emptying
In patients with type 2 diabetes mellitus.
AU Kolterman O; Gottlieb A; Prickett K; Gaines E; Young A.

L636 ANSWER 39 OF 46 ADISCTI COPYRIGHT 2003 (ADIS)
SO Diabetologia (Aug 1, 1999), Vol. 42 (Suppl. 1), pp. 41 (plus oral presentation)
TI AC2993 (synthetic **exendin-4**) lowered postprandial plasma glucose concentrations in people with type 2 diabetes.
ADIS TITLE: **Exendin-4**: pharmacodynamics.
Effect on postprandial glucose levels
In patients with type 2 diabetes mellitus.
AU Kolterman O; Fineman M; Gottlieb A; Petrella E; Pricket K; et al.

L636 ANSWER 40 OF 46 ADISCTI COPYRIGHT 2003 (ADIS)
SO Diabetes (May 1, 1999), Vol. 48 (Suppl. 1), pp. 199
TI **Exendin-4** (AC993) decreases **glucagon secretion** during hyperglycemic clamps in diabetic fatty Zucker rats.
AU Gedulin B; Jodka L; Hoyt J.

L636 ANSWER 41 OF 46 PROMT COPYRIGHT 2003 Gale Group

SO Marketletter, (30 Sep 2002) .
ISSN: ISSN: 0951-3175.
AB In a ringing endorsement for Amylin Pharmaceuticals, Eli Lilly has licensed rights to the former's AC2993 diabetes drug in a deal which could be worth up to $330 million in direct payments, including $80 million in upfront nonrefundable fees, and stock purchases. Amylin's shares had put on nearly 12% to reach $13.88 as this story went to press, while Lilly also posted a small gain to $55.50.

Subscription: 499.00 British pounds per year. Published weekly. 54-55 Wilton Road, London SW1V 1DE., United Kingdom
TI Amylin boosted as Lilly licenses diabetes drug in $330M deal.(Brief Article)

L636 ANSWER 42 OF 46 PROMT COPYRIGHT 2003 Gale Group

SO Marketletter, (24 Aug 1998) pp. N/A.
ISSN: 0951-3175.
AB Amylin of the USA has started clinical trials of its second drug candidate, **exendin-4**, in patients with type 2 diabetes. The drug is a synthetic version of a compound derived from the saliva of the Gila monster, a lizard native to the deserts of Arizona in the USA. The first Phase I study will be conducted in the UK and will look at escalating single doses of subcutaneous **exendin-4** in healthy volunteers. If the results are positive, proof-of-concept

studies in patients with type 2 diabetes could begin in 1999. **Exendin-4** is similar in structure to **glucagon**-like peptide-1, a hormone thought to be important in human glucose metabolism. Clinical data presented at an Eli Lilly meeting in Hamburg, Germany, last year, showed that GLP-1 produces a glucose-dependent stimulation of insulin secretion, an inhibition of **glucagon secretion**, increased rate of proinsulin synthesis and slowed gastric emptying. In addition, animal data has suggested that GLP-1 has insulin-like properties at target tissues (Marketletter May 5, 1997). Lilly is developing synthetic analogs of GLP-1, as the hormone itself has a plasma half-life which is too short to make a commercially-useful product. Amylin notes that **exendin-4** shares many of the properties of GLP-1 but offers a much longer biological duration of action. In animal tests, **exendin-4** stimulated secretion of insulin in hyperglycemia but not hypoglycemic conditions and also modulated gastric emptying. Most importantly, notes Amylin, **exendin-4** achieved a near-normalization of glucose control in an animal model of type 2 diabetes. Chronic administration to obese animals decreased food intake and led to a reduction in weight, suggesting **exendin-4** may also have a role to play in the management of obesity. Amylin's lead product, pramlintide, is currently in four pivotal trials in patients with both type 1 and type 2 diabetes (Marketletters passim).

TI Amylin Starts Trials Of **Exendin-4** In Diabetes

L636 ANSWER 43 OF 46

SO Marketletter, (24 Aug 1998) .
ISSN: 0951-3175.
TI Amylin Starts Trials Of **Exendin-4** In Diabetes

L636 ANSWER 44 OF 46 ADISINSIGHT
SO Adis R&D Insight

L636 ANSWER 45 OF 46 PHARMAML
SO Marketletter September 30, 2002
AN 1665640 PHARMAML
TX In a ringing endorsement for Amylin Pharmaceuticals, Eli Lilly has licensed rights to the former's AC2993 diabetes drug in a deal which could be worth up to $330 million in direct payments, including $80 million in upfront nonrefundable fees, and stock purchases. Amylin's shares had put on nearly 12% to reach $13.88 as this story went to press, while Lilly also posted a small gain to $55.50.

AC2993 is a synthetic form of **exendin-4** which has a number of the biological activities of the hormone **glucagon**-like peptide-1, including the stimulation of insulin secretion in the presence of elevated blood glucose concentrations (but not during periods of low blood glucose concentrations), suppression of **glucagon secretion**, reduction of appetite and delay of food absorption.

However, Amylin's version, which is in Phase III trials, is much longer-acting than the native hormone. It is being developed as a fixed-dose injection in the first instance and could be filed for approval in this form as early as 2004. A key advantage over current therapies for type 2 diabetes is its low propensity to cause weight gain.

Lilly's interest in the compound stems from its own activities in diabetes, with a franchise that includes various forms of insulin and oral antidiabetic agents. Aside from the initial $80 million license fee, the company will buy $30 million-worth of Amylin stock at a premium to the current price, with a further commitment for additional payments of $85 million on the attainment of certain developmental milestones and $135 million on commercialization. Lilly may also make available a $110

million convertible loan to fund a portion of Amylin's development and commercialization costs.

The two companies will share development and marketing costs for the product in the USA, with Lilly picking up 80% and 100% of these costs, respectively, outside this market. Profits will be shared in the USA, and Lilly will get 80% profit share in other countries.

Additionally, the companies have agreed that, for a limited period of time prior to the commercialization of AC2993, Amylin will co-promote Humatrope (somatropin), Lilly's recombinant human growth hormone product, in the USA.

TI Amylin boosted as Lilly licenses diabetes drug in $330M deal

L636 ANSWER 46 OF 46 PHARMAML COPYRIGHT 2003 MARKETLETTER
SO Marketletter August 19, 1998
AN 1643252 PHARMAML
TX Amylin of the USA has started clinical trials of its second drug candidate, **exendin-4**, in patients with type 2 diabetes. The drug is a synthetic version of a compound derived from the saliva of the Gila monster, a lizard native to the deserts of Arizona in the USA.

The first Phase I study will be conducted in the UK and will look at escalating single doses of subcutaneous **exendin-4** in healthy volunteers. If the results are positive, proof-of-concept studies in patients with type 2 diabetes could begin in 1999.

Exendin-4 is similar in structure to **glucagon**-like peptide-1, a hormone thought to be important in human glucose metabolism. Clinical data presented at an Eli Lilly meeting in Hamburg, Germany, last year, showed that GLP-1 produces a glucose-dependent stimulation of insulin secretion, an inhibition of **glucagon secretion**, increased rate of proinsulin synthesis and slowed gastric emptying. In addition, animal data has suggested that GLP-1 has insulin-like properties at target tissues (Marketletter May 5, 1997).

Lilly is developing synthetic analogs of GLP-1, as the hormone itself has a plasma half-life which is too short to make a commercially-useful product. Amylin notes that **exendin-4** shares many of the properties of GLP-1 but offers a much longer biological duration of action.

In animal tests, **exendin-4** stimulated secretion of insulin in hyperglycemia but not hypoglycemic conditions and also modulated gastric emptying. Most importantly, notes Amylin, **exendin-4** achieved a near-normalization of glucose control in an animal model of type 2 diabetes. Chronic administration to obese animals decreased food intake and led to a reduction in weight, suggesting **exendin-4** may also have a role to play in the management of obesity.

Amylin's lead product, pramlintide, is currently in four pivotal trials in patients with both type 1 and type 2 diabetes (Marketletters passim).

TI Amylin Starts Trials Of **Exendin-4** In Diabetes

=>

WEST

Generate Collection | Print

Search Results - Record(s) 1 through 3 of 3 returned.

☐ 1. Document ID: US 20020010133 A1

L2: Entry 1 of 3 File: PGPB Jan 24, 2002

PGPUB-DOCUMENT-NUMBER: 20020010133
PGPUB-FILING-TYPE: new
DOCUMENT-IDENTIFIER: US 20020010133 A1

TITLE: METHOD FOR PREVENTING GASTRITIS USING AMYLIN OR AMYLIN AGONISTS

PUBLICATION-DATE: January 24, 2002

INVENTOR-INFORMATION:

NAME	CITY	STATE	COUNTRY	RULE-47
YOUNG, ANDREW A.	SAN DIEGO	CA	US	
GEDULIN, BRONISLAVA	SAN DIEGO	CA	US	
BEYNON, GARETH W.	BRIGHTWELL-CUM SOTWELL		UA	

US-CL-CURRENT: 514/12; 514/13, 514/14

Full | Title | Citation | Front | Review | Classification | Date | Reference | Sequences | Attachments KWIC | Draw. Desc | Image

☐ 2. Document ID: WO 9850059 A1

L2: Entry 2 of 3 File: EPAB Nov 12, 1998

PUB-NO: WO009850059A1
DOCUMENT-IDENTIFIER: WO 9850059 A1
TITLE: METHOD FOR PREVENTING GASTRITIS USING AMYLIN OR AMYLIN AGONISTS

PUBN-DATE: November 12, 1998

INVENTOR-INFORMATION:

NAME	COUNTRY
YOUNG, ANDREW	US
GEDULIN, BRONISLAVA	US
BEYNON, GARETH WYN	GB

INT-CL (IPC): A61 K 38/10; A61 K 38/16

Full | Title | Citation | Front | Review | Classification | Date | Reference | Sequences | Attachments KWIC | Draw. Desc | Image

☐ 3. Document ID: WO 9805351 A1

L2: Entry 3 of 3 File: EPAB Feb 12, 1998

PUB-NO: WO009805351A1
DOCUMENT-IDENTIFIER: WO 9805351 A1
TITLE: METHODS FOR REGULATING GASTROINTESTINAL MOTILITY

PUBN-DATE: February 12, 1998

INVENTOR-INFORMATION:

NAME	COUNTRY
YOUNG, ANDREW A	US
GEDULIN, BRONISLAVA	US
BEELEY, NIGEL ROBERT ARNOLD	US
PRICKETT, KATHRYN S	US

INT-CL (IPC): A61 K 38/00; A61 K 38/26; G03 F 5/00; C07 K 2/00; C07 K 5/00
EUR-CL (EPC): C07K014/575; A61K038/22

Generate Collection | Print

Term	Documents
GEDULIN-BRONISLAVA.DWPI,EPAB,USPT,PGPB.	3
GEDULIN-BRONISLAVAS	0
GEDULIN-BRONISLAVA.IN..USPT,PGPB,EPAB,DWPI,TDBD.	3
(GEDULIN-BRONISLAVA.IN.).USPT,PGPB,EPAB,DWPI,TDBD.	3

Display Format: - | Change Format

Previous Page Next Page

WEST

Help | Logout | Interrupt

Main Menu | Search Form | Posting Counts | Show S Numbers | Edit S Numbers | Preferences | Cases

Search Results -

Term	Documents
GEDULIN-BRONISLAVA.DWPI,EPAB,USPT,PGPB.	3
GEDULIN-BRONISLAVAS	0
GEDULIN-BRONISLAVA.IN..USPT,PGPB,EPAB,DWPI,TDBD.	3
(GEDULIN-BRONISLAVA.IN.).USPT,PGPB,EPAB,DWPI,TDBD.	3

Database: US Patents Full-Text Database; US Pre-Grant Publication Full-Text Database; JPO Abstracts Database; EPO Abstracts Database; Derwent World Patents Index; IBM Technical Disclosure Bulletins

Search: L2

Refine Search

Recall Text | Clear

Search History

DATE: Friday, January 24, 2003 Printable Copy Create Case

Set Name side by side	Query	Hit Count	Set Name result set
DB=USPT,PGPB,EPAB,DWPI,TDBD; THES=ASSIGNEE; PLUR=YES; OP=ADJ			
L2	gedulin-bronislava.in.	3	L2
L1	young-andrew-a$.in.	20	L1

END OF SEARCH HISTORY

WEST

Generate Collection | Print

Search Results - Record(s) 1 through 3 of 3 returned.

☐ 1. Document ID: US 20030004162 A1

L10: Entry 1 of 3 File: PGPB Jan 2, 2003

PGPUB-DOCUMENT-NUMBER: 20030004162
PGPUB-FILING-TYPE: new
DOCUMENT-IDENTIFIER: US 20030004162 A1

TITLE: Use of glycogen phosphorylase inhibitors

PUBLICATION-DATE: January 2, 2003

INVENTOR-INFORMATION:

NAME	CITY	STATE	COUNTRY	RULE-47
Treadway, Judith L.	Mystic	CT	US	

US-CL-CURRENT: 514/228.2; 514/233.5, 514/254.09, 514/365, 514/415

Full | Title | Citation | Front | Review | Classification | Date | Reference | Sequences | Attachments | Claims | KWIC | Draw Desc | Image

☐ 2. Document ID: US 20020187982 A1

L10: Entry 2 of 3 File: PGPB Dec 12, 2002

PGPUB-DOCUMENT-NUMBER: 20020187982
PGPUB-FILING-TYPE: new
DOCUMENT-IDENTIFIER: US 20020187982 A1

TITLE: Glucagon antagonists/inverse agonists

PUBLICATION-DATE: December 12, 2002

INVENTOR-INFORMATION:

NAME	CITY	STATE	COUNTRY	RULE-47
Behrens, Carsten	Kobenhavn N		DK	
Lau, Jesper	Farum		DK	
Madsen, Peter	Bagsvaerd		DK	

US-CL-CURRENT: 514/235.8; 514/254.03, 514/254.05, 514/326, 514/364, 514/381, 514/567, 544/132, 544/138, 544/367, 546/208 , 546/209, 548/132, 548/252, 562/442

Full | Title | Citation | Front | Review | Classification | Date | Reference | Sequences | Attachments | Claims | KWIC | Draw Desc | Image

☐ 3. Document ID: JP 2002538084 W WO 200041548 A2 AU 200024136 A NO 200103469 A EP 1143989 A2 BR 200007823 A KR 2001086165 A KR 2002001719 A CN 1347327 A

L10: Entry 3 of 3 File: DWPI Nov 12, 2002

DERWENT-ACC-NO: 2000-490999
DERWENT-WEEK: 200275

TITLE: Lowering plasma glucagon using exendin, an exendin agonist, a modified exendin or a modified exendin agonist, useful for treating hyperglucagonemia and diabetes

INVENTOR: GEDULIN, B; YOUNG, A

PRIORITY-DATA: 2000US-175365P (January 10, 2000), 1999US-116380P (January 14, 1999), 1999US-132017P (April 30, 1999)

PATENT-FAMILY:

PUB-NO	PUB-DATE	LANGUAGE	PAGES	MAIN-IPC
JP 2002538084 W	November 12, 2002		104	A61K038/00
WO 200041548 A2	July 20, 2000	E	096	A61K038/28
AU 200024136 A	August 1, 2000		000	A61K038/00
NO 200103469 A	September 14, 2001		000	A61K000/00
EP 1143989 A2	October 17, 2001	E	000	A61K038/00
BR 200007823 A	November 20, 2001		000	A61K038/00
KR 2001086165 A	September 8, 2001		000	A61K038/17
KR 2002001719 A	January 9, 2002		000	A61K038/22
CN 1347327 A	May 1, 2002		000	A61K038/22

INT-CL (IPC): A61 K 0/00; A61 K 38/00; A61 K 38/17; A61 K 38/22; A61 K 38/28; A61 K 45/00; A61 K 47/48; A61 P 5/00; A61 P 5/48; A61 P 17/00; A61 P 35/00; C07 K 14/435

Full | Title | Citation | Front | Review | Classification | Date | Reference | Sequences | Attachments

KWIC | Draw. Desc | Image

Generate Collection | Print

Term	Documents
EXENDIN-4.DWPI,TDBD,EPAB,USPT,PGPB.	65
EXENDIN-4S	0
GLUCAGONOMA.DWPI,TDBD,EPAB,USPT,PGPB.	160
GLUCAGONOMAS.DWPI,TDBD,EPAB,USPT,PGPB.	63
(GLUCAGONOMA AND EXENDIN-4).USPT,PGPB,EPAB,DWPI,TDBD.	3
(EXENDIN-4 AND GLUCAGONOMA).USPT,PGPB,EPAB,DWPI,TDBD.	3

Display Format: - | Change Format

Previous Page Next Page

WEST

Generate Collection | Print

Search Results - Record(s) 1 through 56 of 56 returned.

☐ 1. Document ID: US 20030013646 A1

L8: Entry 1 of 56 File: PGPB Jan 16, 2003

PGPUB-DOCUMENT-NUMBER: 20030013646
PGPUB-FILING-TYPE: new
DOCUMENT-IDENTIFIER: US 20030013646 A1

TITLE: Methods to stimulate insulin production by pancreatic beta-cells

PUBLICATION-DATE: January 16, 2003

INVENTOR-INFORMATION:

NAME	CITY	STATE	COUNTRY	RULE-47
Habener, Joel F.	Newton Centre	MA	US	
Thomas, Melissa K.	Boston	MA	US	

US-CL-CURRENT: 514/12; 424/93.21, 514/44

Full | Title | Citation | Front | Review | Classification | Date | Reference | Sequences | Attachments | KWIC | Draw. Desc | Image

☐ 2. Document ID: US 20030008905 A1

L8: Entry 2 of 56 File: PGPB Jan 9, 2003

PGPUB-DOCUMENT-NUMBER: 20030008905
PGPUB-FILING-TYPE: new
DOCUMENT-IDENTIFIER: US 20030008905 A1

TITLE: Method for the improvement of islet signaling in diabetes mellitus and for its prevention

PUBLICATION-DATE: January 9, 2003

INVENTOR-INFORMATION:

NAME	CITY	STATE	COUNTRY	RULE-47
Demuth, Hans-Ulrich	Halle		DE	
Glund, Konrad	Halle		DE	

US-CL-CURRENT: 514/365; 514/423

Full | Title | Citation | Front | Review | Classification | Date | Reference | Sequences | Attachments | KWIC | Draw. Desc | Image

☐ 3. Document ID: US 20030004162 A1

L8: Entry 3 of 56 File: PGPB Jan 2, 2003

PGPUB-DOCUMENT-NUMBER: 20030004162

PGPUB-FILING-TYPE: new
DOCUMENT-IDENTIFIER: US 20030004162 A1

TITLE: Use of glycogen phosphorylase inhibitors

PUBLICATION-DATE: January 2, 2003

INVENTOR-INFORMATION:

NAME	CITY	STATE	COUNTRY	RULE-47
Treadway, Judith L.	Mystic	CT	US	

US-CL-CURRENT: 514/228.2; 514/233.5, 514/254.09, 514/365, 514/415

Full | Title | Citation | Front | Review | Classification | Date | Reference | Sequences | Attachments KWIC | Draw Desc | Image

---

☐ 4. Document ID: US 20020198242 A1

L8: Entry 4 of 56 File: PGPB Dec 26, 2002

PGPUB-DOCUMENT-NUMBER: 20020198242
PGPUB-FILING-TYPE: new
DOCUMENT-IDENTIFIER: US 20020198242 A1

TITLE: Method for the improvement of islet signaling in diabetes mellitus and for its prevention

PUBLICATION-DATE: December 26, 2002

INVENTOR-INFORMATION:

NAME	CITY	STATE	COUNTRY	RULE-47
Demuth, Hans-Ulrich	Halle		DE	
Glund, Konrad	Halle		DE	

US-CL-CURRENT: 514/365; 514/423

Full | Title | Citation | Front | Review | Classification | Date | Reference | Sequences | Attachments KWIC | Draw Desc | Image

---

☐ 5. Document ID: US 20020193390 A1

L8: Entry 5 of 56 File: PGPB Dec 19, 2002

PGPUB-DOCUMENT-NUMBER: 20020193390
PGPUB-FILING-TYPE: new
DOCUMENT-IDENTIFIER: US 20020193390 A1

TITLE: Pharmaceutical compositions containing an N-(substituted glycyl)-2-cyanopyrrolidine and at least one other antidiabetic agent and their use in inhibiting dipeptidyl peptidase-IV

PUBLICATION-DATE: December 19, 2002

INVENTOR-INFORMATION:

NAME	CITY	STATE	COUNTRY	RULE-47
Villhauer, Edwin Bernard	Morristown	NJ	US	

US-CL-CURRENT: 514/275; 514/343, 514/423, 544/330, 546/279.1, 548/152, 548/537

Full | Title | Citation | Front | Review | Classification | Date | Reference | Sequences | Attachments KWIC | Draw Desc | Image

☐ 6. Document ID: US 20020187982 A1

L8: Entry 6 of 56 File: PGPB Dec 12, 2002

PGPUB-DOCUMENT-NUMBER: 20020187982
PGPUB-FILING-TYPE: new
DOCUMENT-IDENTIFIER: US 20020187982 A1

TITLE: Glucagon antagonists/inverse agonists

PUBLICATION-DATE: December 12, 2002

INVENTOR-INFORMATION:

NAME	CITY	STATE	COUNTRY	RULE-47
Behrens, Carsten	Kobenhavn N		DK	
Lau, Jesper	Farum		DK	
Madsen, Peter	Bagsvaerd		DK	

US-CL-CURRENT: 514/235.8; 514/254.03, 514/254.05, 514/326, 514/364, 514/381, 514/567, 544/132, 544/138, 544/367, 546/208 , 546/209, 548/132, 548/252, 562/442

Full | Title | Citation | Front | Review | Classification | Date | Reference | Sequences | Attachments KWIC | Draw Desc | Image

☐ 7. Document ID: US 20020183369 A1

L8: Entry 7 of 56 File: PGPB Dec 5, 2002

PGPUB-DOCUMENT-NUMBER: 20020183369
PGPUB-FILING-TYPE: new
DOCUMENT-IDENTIFIER: US 20020183369 A1

TITLE: Bicyclic pyrrolyl amides as glycogen phosphorylase inhibitors

PUBLICATION-DATE: December 5, 2002

INVENTOR-INFORMATION:

NAME	CITY	STATE	COUNTRY	RULE-47
Du Bois, Daisy Joe	Palo Alto	CA	US	

US-CL-CURRENT: 514/367; 514/375, 514/393, 514/412, 548/153, 548/217, 548/303.1, 548/453

Full | Title | Citation | Front | Review | Classification | Date | Reference | Sequences | Attachments KWIC | Draw Desc | Image

☐ 8. Document ID: US 20020183367 A1

L8: Entry 8 of 56 File: PGPB Dec 5, 2002

PGPUB-DOCUMENT-NUMBER: 20020183367
PGPUB-FILING-TYPE: new
DOCUMENT-IDENTIFIER: US 20020183367 A1

TITLE: 2,1-Oxazoline and 1,2-pyrazoline-based inhibitors of dipeptidyl peptidase IV

and method

PUBLICATION-DATE: December 5, 2002

INVENTOR-INFORMATION:

NAME	CITY	STATE	COUNTRY	RULE-47
Sulsky, Richard B.	West Trenton	NJ	US	
Robl, Jeffrey A.	Newtown	PA	US	

US-CL-CURRENT: 514/365; 514/374, 514/385, 548/202, 548/215, 548/333.5

Full | Title | Citation | Front | Review | Classification | Date | Reference | Sequences | Attachments | KWIC | Draw. Desc | Image

---

☐ 9. Document ID: US 20020164307 A1

L8: Entry 9 of 56 File: PGPB Nov 7, 2002

PGPUB-DOCUMENT-NUMBER: 20020164307
PGPUB-FILING-TYPE: new
DOCUMENT-IDENTIFIER: US 20020164307 A1

TITLE: Stem cells of the islets of langerhans and their use in treating diabetes mellitus

PUBLICATION-DATE: November 7, 2002

INVENTOR-INFORMATION:

NAME	CITY	STATE	COUNTRY	RULE-47
Habener, Joel F.	Newton Centre	MA	US	
Zulewski, Henryk	Basel	MA	CH	
Thomas, Melissa K.	Boston	MA	US	
Abraham, Elizabeth J.	Quincy	MA	US	
Vallejo, Mario	Madrid		ES	
Leech, Colin A.	Boston		US	

US-CL-CURRENT: 424/93.7; 424/93.21

Full | Title | Citation | Front | Review | Classification | Date | Reference | Sequences | Attachments | KWIC | Draw. Desc | Image

---

☐ 10. Document ID: US 20020151065 A1

L8: Entry 10 of 56 File: PGPB Oct 17, 2002

PGPUB-DOCUMENT-NUMBER: 20020151065
PGPUB-FILING-TYPE: new
DOCUMENT-IDENTIFIER: US 20020151065 A1

TITLE: Induction of beta cell differentiation in human cells by stimulation of the GLP-1 receptor

PUBLICATION-DATE: October 17, 2002

INVENTOR-INFORMATION:

NAME	CITY	STATE	COUNTRY	RULE-47
Levine, Fred	Del Mar	CA	US	
Dufayet, Dominique	San Diego	CA	US	

US-CL-CURRENT: 435/455; 435/366

Full | Title | Citation | Front | Review | Classification | Date | Reference | Sequences | Attachments KWIC | Draw Desc | Image

---

☐ 11. Document ID: US 20020146468 A1

L8: Entry 11 of 56 File: PGPB Oct 10, 2002

PGPUB-DOCUMENT-NUMBER: 20020146468
PGPUB-FILING-TYPE: new
DOCUMENT-IDENTIFIER: US 20020146468 A1

TITLE: Extracts, compounds & pharmaceutical compositions having anti-diabetic activity and their use

PUBLICATION-DATE: October 10, 2002

INVENTOR-INFORMATION:

NAME	CITY	STATE	COUNTRY	RULE-47
Rubin, Ian Duncan	Nottingham	CT	GB	
Bindra, Jasjit Singh	Groton		US	
Cawthorne, Michael Anthony	Buckingham		GB	

US-CL-CURRENT: 424/725

Full | Title | Citation | Front | Review | Classification | Date | Reference | Sequences | Attachments KWIC | Draw Desc | Image

---

☐ 12. Document ID: US 20020146405 A1

L8: Entry 12 of 56 File: PGPB Oct 10, 2002

PGPUB-DOCUMENT-NUMBER: 20020146405
PGPUB-FILING-TYPE: new
DOCUMENT-IDENTIFIER: US 20020146405 A1

TITLE: Treatment of hibernating myocardium and diabetic cardiomyopathy with a GLP-1 peptide

PUBLICATION-DATE: October 10, 2002

INVENTOR-INFORMATION:

NAME	CITY	STATE	COUNTRY	RULE-47
Coolidge, Thomas R.	Falls Village	CT	US	
Ehlers, Mario	Lincoln	NE	US	

US-CL-CURRENT: 424/94.61

Full | Title | Citation | Front | Review | Classification | Date | Reference | Sequences | Attachments KWIC | Draw Desc | Image

---

☐ 13. Document ID: US 20020137666 A1

L8: Entry 13 of 56 File: PGPB Sep 26, 2002

PGPUB-DOCUMENT-NUMBER: 20020137666

PGPUB-FILING-TYPE: new
DOCUMENT-IDENTIFIER: US 20020137666 A1

TITLE: USE OF EXENDINS AND AGONISTS THEREOF FOR THE REDUCTION OF FOOD INTAKE

PUBLICATION-DATE: September 26, 2002

INVENTOR-INFORMATION:

NAME	CITY	STATE	COUNTRY	RULE-47
BEELEY, NIGEL ROBERT ARNOLD	SOLANA BEACH	CA	US	
PRICKETT, KATHRYN S.	SAN DIEGO	CA	US	
BHAVSAR, SUNIL	SAN DIEGO	CA	US	

US-CL-CURRENT: 514/2; 514/12, 530/350

Full | Title | Citation | Front | Review | Classification | Date | Reference | Sequences | Attachments | KWIC | Draw Desc | Image

---

☐ 14. Document ID: US 20020123461 A1

L8: Entry 14 of 56 File: PGPB Sep 5, 2002

PGPUB-DOCUMENT-NUMBER: 20020123461
PGPUB-FILING-TYPE: new
DOCUMENT-IDENTIFIER: US 20020123461 A1

TITLE: Enhancement of GLP-2 activity

PUBLICATION-DATE: September 5, 2002

INVENTOR-INFORMATION:

NAME	CITY	STATE	COUNTRY	RULE-47
Drucker, Daniel J.	Toronto		CA	
Lovshin, Julie Ann Louise	Toronto		CA	

US-CL-CURRENT: 514/8; 514/12

Full | Title | Citation | Front | Review | Classification | Date | Reference | Sequences | Attachments | KWIC | Draw Desc | Image

---

☐ 15. Document ID: US 20020115605 A1

L8: Entry 15 of 56 File: PGPB Aug 22, 2002

PGPUB-DOCUMENT-NUMBER: 20020115605
PGPUB-FILING-TYPE: new
DOCUMENT-IDENTIFIER: US 20020115605 A1

TITLE: Novel peptide with effects on cerebral health

PUBLICATION-DATE: August 22, 2002

INVENTOR-INFORMATION:

NAME	CITY	STATE	COUNTRY	RULE-47
During, Matthew	Philadelphia	PA	US	
Haile, Colin N.	Philadelphia	PA	US	

US-CL-CURRENT: 514/12; 514/16, 530/328

Full | Title | Citation | Front | Review | Classification | Date | Reference | Sequences | Attachments KWIC | Draw Desc | Image

☐ 16. Document ID: US 20020107206 A1

L8: Entry 16 of 56 File: PGPB Aug 8, 2002

PGPUB-DOCUMENT-NUMBER: 20020107206
PGPUB-FILING-TYPE: new
DOCUMENT-IDENTIFIER: US 20020107206 A1

TITLE: Treatment of acute coronary syndrome with GLP-1

PUBLICATION-DATE: August 8, 2002

INVENTOR-INFORMATION:

NAME	CITY	STATE	COUNTRY	RULE-47
Coolidge, Thomas R.	Falls Village	CT	US	
Ehlers, Mario	Lincoln	NE	US	

US-CL-CURRENT: 514/21

Full | Title | Citation | Front | Review | Classification | Date | Reference | Sequences | Attachments KWIC | Draw Desc | Image

☐ 17. Document ID: US 20020099013 A1

L8: Entry 17 of 56 File: PGPB Jul 25, 2002

PGPUB-DOCUMENT-NUMBER: 20020099013
PGPUB-FILING-TYPE: new
DOCUMENT-IDENTIFIER: US 20020099013 A1

TITLE: Active agent delivery systems and methods for protecting and administering active agents

PUBLICATION-DATE: July 25, 2002

INVENTOR-INFORMATION:

NAME	CITY	STATE	COUNTRY	RULE-47
Piccariello, Thomas	Blacksburg	VA	US	
Olon, Lawrence P.	Bristol	TN	US	
Kirk, Randal J.	Radford	VA	US	

US-CL-CURRENT: 514/12

Full | Title | Citation | Front | Review | Classification | Date | Reference | Sequences | Attachments KWIC | Draw Desc | Image

☐ 18. Document ID: US 20020098195 A1

L8: Entry 18 of 56 File: PGPB Jul 25, 2002

PGPUB-DOCUMENT-NUMBER: 20020098195
PGPUB-FILING-TYPE: new
DOCUMENT-IDENTIFIER: US 20020098195 A1

TITLE: Effects of glucagon-like peptide-1 (7-36) on antro-pyloro-duodenal motility

PUBLICATION-DATE: July 25, 2002

INVENTOR-INFORMATION:

NAME	CITY	STATE	COUNTRY	RULE-47
Goeke, Burkhard	Gauting		DE	
Schirra, Joerg	Kirchhain		DE	

US-CL-CURRENT: 424/184.1

Full | Title | Citation | Front | Review | Classification | Date | Reference | Sequences | Attachments | KWIC | Draw Desc | Image

---

☐ 19. Document ID: US 20020065239 A1

L8: Entry 19 of 56 File: PGPB May 30, 2002

PGPUB-DOCUMENT-NUMBER: 20020065239
PGPUB-FILING-TYPE: new
DOCUMENT-IDENTIFIER: US 20020065239 A1

TITLE: Methods and compositions for treatment of diabetes and related conditions via gene therapy

PUBLICATION-DATE: May 30, 2002

INVENTOR-INFORMATION:

NAME	CITY	STATE	COUNTRY	RULE-47
Caplan, Shari L.	Sloatsburg	NY	US	
Boettcher, Brian R.	Morristown	NJ	US	
Slosberg, Eric D.	New York	NY	US	
Connelly, Sheila	Ijamsville	MD	US	
Kaleko, Michael	Rockville	MD	US	
Desai, Urvi J.	Germantown	MD	US	

US-CL-CURRENT: 514/44

Full | Title | Citation | Front | Review | Classification | Date | Reference | Sequences | Attachments | KWIC | Draw Desc | Image

---

☐ 20. Document ID: US 20020058659 A1

L8: Entry 20 of 56 File: PGPB May 16, 2002

PGPUB-DOCUMENT-NUMBER: 20020058659
PGPUB-FILING-TYPE: new
DOCUMENT-IDENTIFIER: US 20020058659 A1

TITLE: Imidazole compounds

PUBLICATION-DATE: May 16, 2002

INVENTOR-INFORMATION:

NAME	CITY	STATE	COUNTRY	RULE-47
Andersen, Knud Erik	Brondby		DK	
Dorwald, Florencio Zaragiza	Ballerup		DK	
Peschke, Bernd	Malov		DK	
Sidelmann, Ulla Grove	Valby		DK	
Rudolf, Klaus	Warthausen		DE	
Stenkamp, Dirk	Biberach		DE	
Hurnaus, Rudolf	Biberach		DE	
Muller, Stephan Georg	Warthausen		DE	
Krist, Bernd	Ulm		DE	
Eriksen, Birgitte	Farum		DE	

US-CL-CURRENT: 514/234.5; 514/314, 514/322, 514/338, 514/366, 514/394, 546/167, 546/273.4, 548/159, 548/304.4

Full | Title | Citation | Front | Review | Classification | Date | Reference | Sequences | Attachments | KWIC | Draw. Desc | Image

---

☐ 21. Document ID: US 20020049153 A1

L8: Entry 21 of 56 File: PGPB Apr 25, 2002

PGPUB-DOCUMENT-NUMBER: 20020049153
PGPUB-FILING-TYPE: new
DOCUMENT-IDENTIFIER: US 20020049153 A1

TITLE: Long lasting insulinoptropic peptides

PUBLICATION-DATE: April 25, 2002

INVENTOR-INFORMATION:

NAME	CITY	STATE	COUNTRY	RULE-47
Bridon, Dominique P.	Outremont	CA	CA	
L'Archeveque, Benoit	Leval		CA	
Ezrin, Alan M.	Moraga		US	
Holmes, Darren L.	Montreal		CA	
Leblanc, Anouk	Montreal		CA	
St. Pierre, Serge	Ile Bizard		CA	

US-CL-CURRENT: 514/3; 514/12, 530/303

Full | Title | Citation | Front | Review | Classification | Date | Reference | Sequences | Attachments | KWIC | Draw. Desc | Image

---

☐ 22. Document ID: US 20020037527 A1

L8: Entry 22 of 56 File: PGPB Mar 28, 2002

PGPUB-DOCUMENT-NUMBER: 20020037527
PGPUB-FILING-TYPE: new
DOCUMENT-IDENTIFIER: US 20020037527 A1

TITLE: High density molecular arrays on porous surfaces

PUBLICATION-DATE: March 28, 2002

INVENTOR-INFORMATION:

NAME	CITY	STATE	COUNTRY	RULE-47
Ellson, Richard N.	Palo Alto	CA	US	
Mutz, Mitchell W.	Palo Alto	CA	US	
Foote, James K.	Cupertino	CA	US	

US-CL-CURRENT: 435/6; 436/518

Full | Title | Citation | Front | Review | Classification | Date | Reference | Sequences | Attachments KWIC | Draw Desc | Image

---

☐ 23. Document ID: US 20020037359 A1

L8: Entry 23 of 56 File: PGPB Mar 28, 2002

PGPUB-DOCUMENT-NUMBER: 20020037359
PGPUB-FILING-TYPE: new
DOCUMENT-IDENTIFIER: US 20020037359 A1

TITLE: Focused acoustic energy in the preparation of peptide arrays

PUBLICATION-DATE: March 28, 2002

INVENTOR-INFORMATION:

NAME	CITY	STATE	COUNTRY	RULE-47
Mutz, Mitchell W.	Palo Alto	CA	US	
Ellson, Richard N.	Palo Alto	CA	US	

US-CL-CURRENT: 427/2.11; 435/176, 530/351, 530/388.1, 530/399

Full | Title | Citation | Front | Review | Classification | Date | Reference | Sequences | Attachments KWIC | Draw Desc | Image

---

☐ 24. Document ID: US 20020019411 A1

L8: Entry 24 of 56 File: PGPB Feb 14, 2002

PGPUB-DOCUMENT-NUMBER: 20020019411
PGPUB-FILING-TYPE: new
DOCUMENT-IDENTIFIER: US 20020019411 A1

TITLE: Cyclopropyl-fused pyrrolidine-based inhibitors of dipeptidyl peptidase IV and method

PUBLICATION-DATE: February 14, 2002

INVENTOR-INFORMATION:

NAME	CITY	STATE	COUNTRY	RULE-47
Robl, Jeffrey A.	Newtown	PA	US	
Sulsky, Richard B.	West Trenton	NJ	US	
Augeri, David J.	Princeton	NJ	US	
Magnin, David R.	Hamilton	NJ	US	
Hamann, Lawrence G.	Cherry Hill	NJ	US	
Betebenner, David A.	Lawrenceville	NJ	US	

US-CL-CURRENT: 514/299; 546/112

Full | Title | Citation | Front | Review | Classification | Date | Reference | Sequences | Attachments KWIC | Draw Desc | Image

☐ 25. Document ID: US 20020010129 A1

L8: Entry 25 of 56 File: PGPB Jan 24, 2002

PGPUB-DOCUMENT-NUMBER: 20020010129
PGPUB-FILING-TYPE: new
DOCUMENT-IDENTIFIER: US 20020010129 A1

TITLE: Shock heat treatment of polypeptides

PUBLICATION-DATE: January 24, 2002

INVENTOR-INFORMATION:

NAME	CITY	STATE	COUNTRY	RULE-47
Matthiesen, Finn	Bronshoj		DK	

US-CL-CURRENT: 514/2; 530/350

Full | Title | Citation | Front | Review | Classification | Date | Reference | Sequences | Attachments | KWIC | Draw Desc | Image

☐ 26. Document ID: US 20010051646 A1

L8: Entry 26 of 56 File: PGPB Dec 13, 2001

PGPUB-DOCUMENT-NUMBER: 20010051646
PGPUB-FILING-TYPE: new
DOCUMENT-IDENTIFIER: US 20010051646 A1

TITLE: Method for the improvement of islet signaling in diabetes mellitus and for its prevention

PUBLICATION-DATE: December 13, 2001

INVENTOR-INFORMATION:

NAME	CITY	STATE	COUNTRY	RULE-47
Demuth, Hans-Ulrich	Halle		DE	
Glund, Konrad	Halle		DE	

US-CL-CURRENT: 514/369; 514/423

Full | Title | Citation | Front | Review | Classification | Date | Reference | Sequences | Attachments | KWIC | Draw Desc | Image

☐ 27. Document ID: US 20010049385 A1

L8: Entry 27 of 56 File: PGPB Dec 6, 2001

PGPUB-DOCUMENT-NUMBER: 20010049385
PGPUB-FILING-TYPE: new
DOCUMENT-IDENTIFIER: US 20010049385 A1

TITLE: Imidazo heterocyclic compounds

PUBLICATION-DATE: December 6, 2001

INVENTOR-INFORMATION:

NAME	CITY	STATE	COUNTRY	RULE-47
Andersen, Knud Erik	Brondby		DK	
Dorwald, Florencio Zaragoza	Ballerup		DK	
Peschke, Bernd	Malov		DK	

US-CL-CURRENT: 514/394; 548/303.1, 548/304.4, 548/304.7

Full | Title | Citation | Front | Review | Classification | Date | Reference | Sequences | Attachments KWIC | Draw. Desc | Image

---

☐ 28. Document ID: US 20010047084 A1

L8: Entry 28 of 56 File: PGPB Nov 29, 2001

PGPUB-DOCUMENT-NUMBER: 20010047084
PGPUB-FILING-TYPE: new
DOCUMENT-IDENTIFIER: US 20010047084 A1

TITLE: Extendin derivatives

PUBLICATION-DATE: November 29, 2001

INVENTOR-INFORMATION:

NAME	CITY	STATE	COUNTRY	RULE-47
Knudsen, Liselotte Bjerre	Valby		DK	
Huusfeldt, Per Olaf	Copenhagen K		DK	
Nielsen, Per Franklin	Vaerlose		DK	
Madsen, Kjeld	Vaerlose		DK	

US-CL-CURRENT: 530/399

Full | Title | Citation | Front | Review | Classification | Date | Reference | Sequences | Attachments KWIC | Draw. Desc | Image

---

☐ 29. Document ID: US 20010046489 A1

L8: Entry 29 of 56 File: PGPB Nov 29, 2001

PGPUB-DOCUMENT-NUMBER: 20010046489
PGPUB-FILING-TYPE: new
DOCUMENT-IDENTIFIER: US 20010046489 A1

TITLE: Stem cells of the islets of langerhans and their use in treating diabetes mellitus

PUBLICATION-DATE: November 29, 2001

INVENTOR-INFORMATION:

NAME	CITY	STATE	COUNTRY	RULE-47
Habener, Joel E.	Newton Center	MA	US	
Zulewski, Henryk	Geneva	MA	CH	
Abraham, Elizabeth J.	Quincy	MA	US	
Thomas, Melissa K.	Boston		US	
Vallejo, Mario	Madrid		ES	

US-CL-CURRENT: 424/93.21; 424/152.1, 435/366, 514/9

☐ 30. Document ID: US 20010038862 A1

L8: Entry 30 of 56 File: PGPB Nov 8, 2001

PGPUB-DOCUMENT-NUMBER: 20010038862
PGPUB-FILING-TYPE: new
DOCUMENT-IDENTIFIER: US 20010038862 A1

TITLE: Topical and transdermal administration of peptidyl durgs using hydroxide releasing agents as permeation enhancers

PUBLICATION-DATE: November 8, 2001

INVENTOR-INFORMATION:

NAME	CITY	STATE	COUNTRY	RULE-47
Luo, Eric C.	Plano	TX	US	
Hsu, Tsung-Min	San Diego	CA	US	

US-CL-CURRENT: 424/688; 514/2

☐ 31. Document ID: US 20010024824 A1

L8: Entry 31 of 56 File: PGPB Sep 27, 2001

PGPUB-DOCUMENT-NUMBER: 20010024824
PGPUB-FILING-TYPE: new
DOCUMENT-IDENTIFIER: US 20010024824 A1

TITLE: Stem cells and their use in transplantation

PUBLICATION-DATE: September 27, 2001

INVENTOR-INFORMATION:

NAME	CITY	STATE	COUNTRY	RULE-47
Moss, Peter Ian	London		GB	
Walters, David Martin	London		GB	
Pointer, Graham	London		GB	

US-CL-CURRENT: 435/366; 424/93.7

☐ 32. Document ID: US 20010012829 A1

L8: Entry 32 of 56 File: PGPB Aug 9, 2001

PGPUB-DOCUMENT-NUMBER: 20010012829
PGPUB-FILING-TYPE: new
DOCUMENT-IDENTIFIER: US 20010012829 A1

TITLE: Transepithelial delivery GLP-1 derivatives

PUBLICATION-DATE: August 9, 2001

INVENTOR-INFORMATION:

NAME	CITY	STATE	COUNTRY	RULE-47
Anderson, Keith	San Diego	CA	US	
Agerso, Henrik	Fredensborg		DK	

US-CL-CURRENT: 514/12; 424/43

Full | Title | Citation | Front | Review | Classification | Date | Reference | Sequences | Attachments KWIC | Draw. Desc | Image

---

☐ 33. Document ID: US 6506724 B1

L8: Entry 33 of 56 File: USPT Jan 14, 2003

US-PAT-NO: 6506724
DOCUMENT-IDENTIFIER: US 6506724 B1

TITLE: Use of exendins and agonists thereof for the treatment of gestational diabetes mellitus

DATE-ISSUED: January 14, 2003

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Hiles; Richard A.	San Diego	CA		
Prickett; Kathryn S.	San Diego	CA		

US-CL-CURRENT: 514/2; 514/12, 514/3, 514/4, 514/866, 530/300, 530/324, 530/325

Full | Title | Citation | Front | Review | Classification | Date | Reference | Sequences | Attachments KWIC | Draw. Desc | Image

---

☐ 34. Document ID: US 6500804 B2

L8: Entry 34 of 56 File: USPT Dec 31, 2002

US-PAT-NO: 6500804
DOCUMENT-IDENTIFIER: US 6500804 B2

TITLE: Method for the improvement of islet signaling in diabetes mellitus and for its prevention

DATE-ISSUED: December 31, 2002

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Demuth; Hans-Ulrich	Halle			DE
Glund; Konrad	Halle			DE

US-CL-CURRENT: 514/19; 514/365, 514/866

Full | Title | Citation | Front | Review | Classification | Date | Reference | Sequences | Attachments KWIC | Draw. Desc | Image

---

☐ 35. Document ID: US 6469021 B1

L8: Entry 35 of 56 File: USPT Oct 22, 2002

US-PAT-NO: 6469021
DOCUMENT-IDENTIFIER: US 6469021 B1

TITLE: Non-peptide antagonists of GLP-1 receptor and methods of use

DATE-ISSUED: October 22, 2002

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Truesdale; Larry Kenneth	San Diego	CA		
Bychowski; Richard A.	Cardiff	CA		
Gonzalez; Javier	Oceanside	CA		
Kuki; Atsuo	Encinitas	CA		
Rajapakse; Ranjan Jagath	San Diego	CA		
Teng; Min	San Diego	CA		
Kiel; Dan	San Diego	CA		
Dhanoa; Daljit S.	West Chester	PA		
Hong; Yufeng	San Diego	CA		
Chou; Tso-sheng	San Diego	CA		
Ling; Anthony L.	San Diego	CA		
Johnson; Michael David	Cardiff	CA		
Gregor; Vlad Edward	San Diego	CA		

US-CL-CURRENT: 514/292; 514/232.8, 514/248, 514/287, 544/126, 544/233, 544/361, 546/64, 546/85, 546/87

Full | Title | Citation | Front | Review | Classification | Date | Reference | Sequences | Attachments KWIC | Draw Desc | Image

---

☐ 36. Document ID: US 6451974 B1

L8: Entry 36 of 56 File: USPT Sep 17, 2002

US-PAT-NO: 6451974
DOCUMENT-IDENTIFIER: US 6451974 B1

TITLE: Method of acylating peptides and novel acylating agents

DATE-ISSUED: September 17, 2002

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Hansen; Louis Brammer	V.ae butted.rl.o slashed.se			DK

US-CL-CURRENT: 530/345; 436/86, 436/90, 530/308, 530/333, 530/402

Full | Title | Citation | Front | Review | Classification | Date | Reference | Sequences | Attachments KWIC | Draw Desc | Image

---

☐ 37. Document ID: US 6448045 B1

L8: Entry 37 of 56 File: USPT Sep 10, 2002

US-PAT-NO: 6448045
DOCUMENT-IDENTIFIER: US 6448045 B1

TITLE: Inducing insulin gene expression in pancreas cells expressing recombinant PDX-1

DATE-ISSUED: September 10, 2002

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Levine; Fred	Del Mar	CA		
Dufayet; Dominique	San Diego	CA		

US-CL-CURRENT: 435/70.1; 435/455

Full | Title | Citation | Front | Review | Classification | Date | Reference | Sequences | Attachments | KWIC | Draw Desc | Image

---

☐ 38. Document ID: US 6437147 B1

L8: Entry 38 of 56 File: USPT Aug 20, 2002

US-PAT-NO: 6437147
DOCUMENT-IDENTIFIER: US 6437147 B1

TITLE: Imidazole compounds

DATE-ISSUED: August 20, 2002

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Andersen; Knud Erik	Brondby			DK
Dorwald; Florencio Zaragoza	Ballerup			DK
Peschke; Bernd	Malov			DK
Sidelmann; Ulla Grove	Vedb.ae butted.k			DK
Rudolf; Klaus	Warthausen			DE
Stenkamp; Dirk	Birberach			DE
Hurnaus; Rudolf	Birberach			DE
Muller; Stephan Georg	Warthausen			DE
Krist; Bernd	Ulm			DE
Eriksen; Birgitte	Farum			DE

US-CL-CURRENT: 548/304.1; 548/302.7

Full | Title | Citation | Front | Review | Classification | Date | Reference | Sequences | Attachments | KWIC | Draw Desc | Image

---

☐ 39. Document ID: US 6432969 B1

L8: Entry 39 of 56 File: USPT Aug 13, 2002

US-PAT-NO: 6432969
DOCUMENT-IDENTIFIER: US 6432969 B1

TITLE: N-(substituted glycyl)-2 cyanopyrrolidines, pharmaceutical compositions containing them and their use in inhibiting dipeptidyl peptidase-IV

DATE-ISSUED: August 13,. 2002

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Villhauer; Edwin Bernard	Morristown	NJ		

US-CL-CURRENT: 514/275; 514/256, 514/343, 514/423, 544/332, 546/208, 546/279.1, 548/540

Full | Title | Citation | Front | Review | Classification | Date | Reference | Sequences | Attachments | KWIC | Draw Desc | Image

---

☐ 40. Document ID: US 6399601 B1

L8: Entry 40 of 56 File: USPT Jun 4, 2002

US-PAT-NO: 6399601
DOCUMENT-IDENTIFIER: US 6399601 B1

TITLE: Bicyclic pyrrolyl amides as glycogen phosphorylase inhibitors

DATE-ISSUED: June 4, 2002

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Du Bois; Daisy Joe	Palo Alto	CA		

US-CL-CURRENT: 514/233.8; 206/566, 514/321, 514/365, 514/419, 544/143, 546/198, 548/181, 548/453

Full | Title | Citation | Front | Review | Classification | Date | Reference | Sequences | Attachments | KWIC | Draw Desc | Image

---

☐ 41. Document ID: US 6395767 B2

L8: Entry 41 of 56 File: USPT May 28, 2002

US-PAT-NO: 6395767
DOCUMENT-IDENTIFIER: US 6395767 B2

TITLE: Cyclopropyl-fused pyrrolidine-based inhibitors of dipeptidyl peptidase IV and method

DATE-ISSUED: May 28, 2002

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Robl; Jeffrey A.	Newtown	PA		
Sulsky; Richard B.	West Trenton	NJ		
Augeri; David J.	Princeton	NJ		
Magnin; David R.	Hamilton	NJ		
Hamann; Lawrence G.	Cherry Hill	NJ		
Betebenner; David A.	Lawrenceville	NJ		

US-CL-CURRENT: 514/412; 548/452

Full | Title | Citation | Front | Review | Classification | Date | Reference | Sequences | Attachments | KWIC | Draw Desc | Image

☐ 42. Document ID: US 6376549 B1

L8: Entry 42 of 56 File: USPT Apr 23, 2002

US-PAT-NO: 6376549
DOCUMENT-IDENTIFIER: US 6376549 B1

TITLE: Metforimin-containing compositions for the treatment of diabetes

DATE-ISSUED: April 23, 2002

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Fine; Stuart A.	Northbrook	IL		
Kinsella; Kevin J.	La Jolla	CA		

US-CL-CURRENT: 514/635; 424/617, 424/626, 424/639, 424/655

Full | Title | Citation | Front | Review | Classification | Date | Reference | Sequences | Attachments | KWIC | Draw. Desc | Image

☐ 43. Document ID: US 6329336 B1

L8: Entry 43 of 56 File: USPT Dec 11, 2001

US-PAT-NO: 6329336
DOCUMENT-IDENTIFIER: US 6329336 B1

TITLE: Long lasting insulinotropic peptides

DATE-ISSUED: December 11, 2001

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Bridon; Dominique P.	Outremont			CA
L'Archeveque; Benoit	Laval			CA
Ezrin; Alan M.	Moraga	CA		
Holmes; Darren L.	Montreal			CA
Leblanc; Anouk	Montreal			CA
St. Pierre; Serge	Ile Bizard			CA

US-CL-CURRENT: 514/2; 514/12

Full | Title | Citation | Front | Review | Classification | Date | Reference | Sequences | Attachments | KWIC | Draw. Desc | Image

☐ 44. Document ID: US 6074875 A

L8: Entry 44 of 56 File: USPT Jun 13, 2000

US-PAT-NO: 6074875
DOCUMENT-IDENTIFIER: US 6074875 A

TITLE: Materials and methods relating to the regulation of polypeptide production in cells

DATE-ISSUED: June 13, 2000

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Thorens; Bernard	Epalinge			CH

US-CL-CURRENT: 435/455; 435/325, 435/354, 435/358, 435/366

Full | Title | Citation | Front | Review | Classification | Date | Reference | Sequences | Attachments | KWMC | Draw Desc | Image

---

☐ 45. Document ID: US 6051557 A

L8: Entry 45 of 56 File: USPT Apr 18, 2000

US-PAT-NO: 6051557
DOCUMENT-IDENTIFIER: US 6051557 A

TITLE: Methods of enhancing functioning of the upper gastrointestinal tract

DATE-ISSUED: April 18, 2000

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Drucker; Daniel J.	Ontario			CA

US-CL-CURRENT: 514/12; 435/366, 530/308, 530/324

Full | Title | Citation | Front | Review | Classification | Date | Reference | Sequences | Attachments | KWMC | Draw Desc | Image

---

☐ 46. Document ID: US 5846937 A

L8: Entry 46 of 56 File: USPT Dec 8, 1998

US-PAT-NO: 5846937
DOCUMENT-IDENTIFIER: US 5846937 A

TITLE: Method of using exendin and GLP-1 to affect the central nervous system

DATE-ISSUED: December 8, 1998

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Drucker; Daniel J.	Toronto			CA

US-CL-CURRENT: 514/12; 514/2, 530/350, 530/399

Full | Title | Citation | Front | Review | Classification | Date | Reference | Sequences | Attachments | KWMC | Draw Desc | Image

---

☐ 47. Document ID: US 5424286 A

L8: Entry 47 of 56 File: USPT Jun 13, 1995

US-PAT-NO: 5424286
DOCUMENT-IDENTIFIER: US 5424286 A

TITLE: Exendin-3 and exendin-4 polypeptides, and pharmaceutical compositions comprising same

DATE-ISSUED: June 13, 1995

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Eng; John	Bronx	NY	10471	

US-CL-CURRENT: 514/2; 435/69.1, 514/866, 530/324

Full | Title | Citation | Front | Review | Classification | Date | Reference | Sequences | Attachments | KWIC | Draw. Desc | Image

---

☐ 48. Document ID: DE 19921537 A1

L8: Entry 48 of 56 File: EPAB Nov 23, 2000

PUB-NO: DE019921537A1
DOCUMENT-IDENTIFIER: DE 19921537 A1
TITLE: Treating carbohydrate metabolism disorders, especially diabetes, comprises activating insulin-secreting b-cells using glucagon-related peptide, glucose-dependent insulinotropic polypeptide, exendin-4 or related drugs

PUBN-DATE: November 23, 2000

INVENTOR-INFORMATION:

NAME	COUNTRY
HOERSCH, DIETER	DE

INT-CL (IPC): A61 K 38/22; A61 K 38/26
EUR-CL (EPC): A61K038/26

Full | Title | Citation | Front | Review | Classification | Date | Reference | Sequences | Attachments | KWIC | Draw. Desc | Image

---

☐ 49. Document ID: AU 200239384 A WO 200247716 A2

L8: Entry 49 of 56 File: DWPI Jun 24, 2002

DERWENT-ACC-NO: 2002-519755
DERWENT-WEEK: 200267

TITLE: Normalization of blood glucose levels, useful for e.g. treating hyperglycemia, diabetes, obesity, stroke or myocardial infarction, preventing cell deterioration or inducing weight loss, comprises use of glucagon-like peptides

INVENTOR: DODD, S W; MACE, K F ; TRAUTMANN, M E

PRIORITY-DATA: 2001US-298652P (June 15, 2001), 2000US-255251P (December 13, 2000), 2001US-295655P (June 4, 2001)

PATENT-FAMILY:

PUB-NO	PUB-DATE	LANGUAGE	PAGES	MAIN-IPC
AU 200239384 A	June 24, 2002		000	A61K038/26
WO 200247716 A2	June 20, 2002	E	087	A61K038/26

INT-CL (IPC): A61 K 38/26

Full | Title | Citation | Front | Review | Classification | Date | Reference | Sequences | Attachments KWIC | Draw. Desc | Image

☐ 50. Document ID: EP 1246638 A1 WO 200151078 A1 AU 200126380 A

L8: Entry 50 of 56 File: DWPI Oct 9, 2002

DERWENT-ACC-NO: 2001-514422
DERWENT-WEEK: 200267
COPYRIGHT 2003 DERWENT INFORMATION LTD
TITLE: Use of exendin and exendin agonist compounds for modulating triglyceride levels, and treating heart disease and dyslipidemia

INVENTOR: KOLTERMAN, O G; YOUNG, A A

PRIORITY-DATA: 2000US-175365P (January 10, 2000)

PATENT-FAMILY:

PUB-NO	PUB-DATE	LANGUAGE	PAGES	MAIN-IPC
EP 1246638 A1	October 9, 2002	E	000	A61K038/22
WO 200151078 A1	July 19, 2001	E	161	A61K038/22
AU 200126380 A	July 24, 2001		000	A61K038/22

INT-CL (IPC): A61 K 31/20; A61 K 31/22; A61 K 31/365; A61 K 31/40; A61 K 31:20; A61 K 31:22; A61 K 31:365; A61 K 31:40; A61 K 38/22; A61 K 38:22; A61 P 3/06; A61 K 38/22; A61 K 38/22; A61 K 38/22; A61 K 38/22; A61 K 31:40; A61 K 31:365; A61 K 31:22; A61 K 31:20

Full | Title | Citation | Front | Review | Classification | Date | Reference | Sequences | Attachments KWIC | Draw. Desc | Image

☐ 51. Document ID: EP 1257282 A1 WO 200139784 A1 AU 200118173 A US 20010024824 A1 US 20010046489 A1 US 20020164307 A1

L8: Entry 51 of 56 File: DWPI Nov 20, 2002

DERWENT-ACC-NO: 2001-408256
DERWENT-WEEK: 200301
COPYRIGHT 2003 DERWENT INFORMATION LTD
TITLE: Treating diabetes mellitus or liver disease, comprises isolating a nestin-positive pancreatic stem cell from a pancreatic islet of a donor, and transferring the stem cell into the patient

INVENTOR: ABRAHAM, E J; FAUSTMAN, D ; HABENER, J L ; THOMAS, M K ; VALLEJO, M ; ZULEWSKI, H ; MOSS, P I ; POINTER, G ; WALTERS, D M ; HABENER, J E ; HABENER, J F ; LEECH, C A

PRIORITY-DATA: 2000US-238880P (October 6, 2000), 1999US-169082P (December 6, 1999), 2000US-215109P (June 28, 2000), 2000US-0731255 (December 6, 2000), 2000US-0731261 (December 6, 2000), 2001US-0963875 (September 26, 2001)

PATENT-FAMILY:

PUB-NO	PUB-DATE	LANGUAGE	PAGES	MAIN-IPC
EP 1257282 A1	November 20, 2002	E	000	A61K035/00
WO 200139784 A1	June 7, 2001	E	102	A61K035/00
AU 200118173 A	June 12, 2001		000	A61K035/00
US 20010024824 A1	September 27, 2001		000	C12N005/08
US 20010046489 A1	November 29, 2001		000	A61K048/00
US 20020164307 A1	November 7, 2002		000	A61K048/00

INT-CL (IPC): A61 K 35/00; A61 K 39/395; A61 K 45/00; A61 K 48/00; C12 N 5/08; C12 N 15/85

Full | Title | Citation | Front | Review | Classification | Date | Reference | Sequences | Attachments | KWIC | Draw. Desc | Image

---

☐ 52. Document ID: WO 200104156 A1 EP 1196444 A1 EP 1076066 A1 AU 200059660 A

L8: Entry 52 of 56 File: DWPI Jan 18, 2001

DERWENT-ACC-NO: 2001-159381
DERWENT-WEEK: 200233
COPYRIGHT 2003 DERWENT INFORMATION LTD
TITLE: Novel peptide agonist of Glucagon-like peptide, useful for decreasing the level of blood glucose and for treating diseases like diabetes, obesity and eating disorders

INVENTOR: LARSEN, B D; MIKKELSEN, J D ; NEVE, S

PRIORITY-DATA: 1999EP-0610043 (August 9, 1999), 1999US-143591P (July 12, 1999)

PATENT-FAMILY:

PUB-NO	PUB-DATE	LANGUAGE	PAGES	MAIN-IPC
WO 200104156 A1	January 18, 2001	E	083	C07K014/575
EP 1196444 A1	April 17, 2002	E	000	C07K014/575
EP 1076066 A1	February 14, 2001	E	000	C07K014/575
AU 200059660 A	January 30, 2001		000	C07K014/575

INT-CL (IPC): A61 K 38/22; A61 K 47/48; A61 P 3/10; C07 K 14/575

Full | Title | Citation | Front | Review | Classification | Date | Reference | Sequences | Attachments | KWIC | Draw. Desc | Image

---

☐ 53. Document ID: DE 19921537 A1

L8: Entry 53 of 56 File: DWPI Nov 23, 2000

DERWENT-ACC-NO: 2001-050874
DERWENT-WEEK: 200107
COPYRIGHT 2003 DERWENT INFORMATION LTD
TITLE: Treating carbohydrate metabolism disorders, especially diabetes, comprises activating insulin-secreting b-cells using glucagon-related peptide, glucose-dependent insulinotropic polypeptide, exendin-4 or related drugs

INVENTOR: HOERSCH, D

PRIORITY-DATA: 1999DE-1021537 (May 11, 1999)

PATENT-FAMILY:

PUB-NO	PUB-DATE	LANGUAGE	PAGES	MAIN-IPC
DE 19921537 A1	November 23, 2000		010	A61K038/22

INT-CL (IPC): A61 K 38/22; A61 K 38/26

Full | Title | Citation | Front | Review | Classification | Date | Reference | Sequences | Attachments KWIC | Draw Desc | Image

---

☐ 54. Document ID: WO 200069911 A1 AU 200048555 A US 6329336 B1 EP 1180121 A1 NO 200105584 A BR 200010750 A US 20020049153 A1 CN 1350548 A

L8: Entry 54 of 56 File: DWPI Nov 23, 2000

DERWENT-ACC-NO: 2001-025008
DERWENT-WEEK: 200259
COPYRIGHT 2003 DERWENT INFORMATION LTD
TITLE: Novel modified insulinotropic peptides for treating diabetes, nervous system disorders and for post surgery treatment, has reactive groups which react with amino, hydroxy or thiol groups on blood components

INVENTOR: BRIDON, D P; EZRIN, A M ; HOLMES, D L ; LARCHEVEQUE, B ; LEBLANC, A ; ST PIERRE, S ; L'ARCHEVEQUE, B ; BRIDON, D

PRIORITY-DATA: 1999US-159783P (October 15, 1999), 1999US-134406P (May 17, 1999), 2000US-0623618 (September 5, 2000), 2001US-0876388 (June 6, 2001)

PATENT-FAMILY:

PUB-NO	PUB-DATE	LANGUAGE	PAGES	MAIN-IPC
WO 200069911 A1	November 23, 2000	E	096	C07K014/605
AU 200048555 A	December 5, 2000		000	C07K014/605
US 6329336 B1	December 11, 2001		000	A01N037/18
EP 1180121 A1	February 20, 2002	E	000	C07K014/605
NO 200105584 A	January 3, 2002		000	C07K000/00
BR 200010750 A	February 26, 2002		000	C07K014/605
US 20020049153 A1	April 25, 2002		000	A61K038/28
CN 1350548 A	May 22, 2002		000	C07K014/605

INT-CL (IPC): A01 K 38/00; A01 N 37/18; A61 K 38/00; A61 K 38/26; A61 K 38/28; A61 P 3/08; C07 K 0/00; C07 K 14/575; C07 K 14/605; C07 K 14/62

Full | Title | Citation | Front | Review | Classification | Date | Reference | Sequences | Attachments KWIC | Draw Desc | Image

---

☐ 55. Document ID: JP 2002538084 W WO 200041548 A2 AU 200024136 A NO 200103469 A EP 1143989 A2 BR 200007823 A KR 2001086165 A KR 2002001719 A CN 1347327 A

L8: Entry 55 of 56 File: DWPI Nov 12, 2002

DERWENT-ACC-NO: 2000-490999
DERWENT-WEEK: 200275
COPYRIGHT 2003 DERWENT INFORMATION LTD
TITLE: Lowering plasma glucagon using exendin, an exendin agonist, a modified exendin or a modified exendin agonist, useful for treating hyperglucagonemia and diabetes

INVENTOR: GEDULIN, B; YOUNG, A

PRIORITY-DATA: 2000US-175365P (January 10, 2000), 1999US-116380P (January 14, 1999), 1999US-132017P (April 30, 1999)

PATENT-FAMILY:

PUB-NO	PUB-DATE	LANGUAGE	PAGES	MAIN-IPC
JP 2002538084 W	November 12, 2002		104	A61K038/00
WO 200041548 A2	July 20, 2000	E	096	A61K038/28
AU 200024136 A	August 1, 2000		000	A61K038/00
NO 200103469 A	September 14, 2001		000	A61K000/00
EP 1143989 A2	October 17, 2001	E	000	A61K038/00
BR 200007823 A	November 20, 2001		000	A61K038/00
KR 2001086165 A	September 8, 2001		000	A61K038/17
KR 2002001719 A	January 9, 2002		000	A61K038/22
CN 1347327 A	May 1, 2002		000	A61K038/22

INT-CL (IPC): A61 K 0/00; A61 K 38/00; A61 K 38/17; A61 K 38/22; A61 K 38/28; A61 K 45/00; A61 K 47/48; A61 P 5/00; A61 P 5/48; A61 P 17/00; A61 P 35/00; C07 K 14/435

Full | Title | Citation | Front | Review | Classification | Date | Reference | Sequences | Attachments | KWMC | Draw Desc | Image

☐ 56. Document ID: US 5424286 A

L8: Entry 56 of 56 File: DWPI Jun 13, 1995

DERWENT-ACC-NO: 1995-262627
DERWENT-WEEK: 199534
COPYRIGHT 2003 DERWENT INFORMATION LTD
TITLE: Stimulating/inhibiting insulin release with exendin polypeptide(s) - for treating diabetes mellitus and preventing hyperglycaemia.

INVENTOR: ENG, J

PRIORITY-DATA: 1993US-0066480 (May 24, 1993)

PATENT-FAMILY:

PUB-NO	PUB-DATE	LANGUAGE	PAGES	MAIN-IPC
US 5424286 A	June 13, 1995		017	A61K038/16

INT-CL (IPC): A61 K 38/16; C07 K 14/46; C12 N 15/63

Full | Title | Citation | Front | Review | Classification | Date | Reference | Sequences | Attachments | KWMC | Draw Desc | Image

Generate Collection | Print

Term	Documents
EXENDIN-4.DWPI,TDBD,EPAB,USPT,PGPB.	65
EXENDIN-4S	0
GLUCAGON.DWPI,TDBD,EPAB,USPT,PGPB.	4444
GLUCAGONS.DWPI,TDBD,EPAB,USPT,PGPB.	49
(EXENDIN-4 AND GLUCAGON).USPT,PGPB,EPAB,DWPI,TDBD.	56
(EXENDIN-4 AND GLUCAGON).USPT,PGPB,EPAB,DWPI,TDBD.	56

Display Format: [ ] Change Format

Previous Page Next Page

WEST Search History

DATE: Friday, January 24, 2003

Set Name side by side	Query	Hit Count	Set Name result set
	DB=USPT,PGPB,EPAB,DWPI,TDBD; THES=ASSIGNEE; PLUR=YES; OP=ADJ		
L10	exendin-4 and glucagonoma	3	L10
L9	exendin-4 and (necrolytic adj migratory adj erythema)	0	L9
L8	exendin-4 and glucagon	56	L8
L7	exendin-4 and (glucagon and (necrolytic adj migratory adj erythema) and glucagonoma)	0	L7
L6	exendin-4	65	L6
L5	6348567.pn.	2	L5
L4	5348461.pn.	2	L4
L3	5846937.pn.	2	L3
L2	5424286.pn.	2	L2
L1	5424286.pn.	2	L1

END OF SEARCH HISTORY

WEST

Generate Collection | Print

Search Results - Record(s) 1 through 20 of 20 returned.

☐ 1. Document ID: US 20020141985 A1

L1: Entry 1 of 20 File: PGPB Oct 3, 2002

PGPUB-DOCUMENT-NUMBER: 20020141985
PGPUB-FILING-TYPE: new
DOCUMENT-IDENTIFIER: US 20020141985 A1

TITLE: Peptide YY and peptide YY agonists for treatment of metabolic disorders

PUBLICATION-DATE: October 3, 2002

INVENTOR-INFORMATION:

NAME	CITY	STATE	COUNTRY	RULE-47
Pittner, Richard A.	San Diego	CA	US	
Young, Andrew A.	La Jolla	CA	US	
Paterniti, James R. JR.	San Diego	CA	US	

US-CL-CURRENT: 424/94.1

Full | Title | Citation | Front | Review | Classification | Date | Reference | Sequences | Attachments KWIC | Draw. Desc | Image

☐ 2. Document ID: US 20020010133 A1

L1: Entry 2 of 20 File: PGPB Jan 24, 2002

PGPUB-DOCUMENT-NUMBER: 20020010133
PGPUB-FILING-TYPE: new
DOCUMENT-IDENTIFIER: US 20020010133 A1

TITLE: METHOD FOR PREVENTING GASTRITIS USING AMYLIN OR AMYLIN AGONISTS

PUBLICATION-DATE: January 24, 2002

INVENTOR-INFORMATION:

NAME	CITY	STATE	COUNTRY	RULE-47
YOUNG, ANDREW A.	SAN DIEGO	CA	US	
GEDULIN, BRONISLAVA	SAN DIEGO	CA	US	
BEYNON, GARETH W.	BRIGHTWELL-CUM SOTWELL		UA	

US-CL-CURRENT: 514/12; 514/13, 514/14

Full | Title | Citation | Front | Review | Classification | Date | Reference | Sequences | Attachments KWIC | Draw. Desc | Image

☐ 3. Document ID: US 6114304 A

L1: Entry 3 of 20 File: USPT Sep 5, 2000

US-PAT-NO: 6114304
DOCUMENT-IDENTIFIER: US 6114304 A

TITLE: Methods for regulating gastrointestinal motility

DATE-ISSUED: September 5, 2000

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Kolterman; Orville G.	Poway	CA		
Young; Andrew A.	Alpine	CA		
Rink; Timothy J.	La Jolla	CA		
Brown; Kathleen Ann Keiting	Wake Forest	NC		

US-CL-CURRENT: 514/12; 514/3

Full | Title | Citation | Front | Review | Classification | Date | Reference | Sequences | Attachments KWIC | Draw Desc | Image

---

☐ 4. Document ID: US 6048514 A

L1: Entry 4 of 20 File: USPT Apr 11, 2000

US-PAT-NO: 6048514
DOCUMENT-IDENTIFIER: US 6048514 A

TITLE: Amylin activity assays

DATE-ISSUED: April 11, 2000

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Young; Andrew A.	San Diego	CA		
Cooper; Garth J. S.	Solana Beach	CA		
Rink; Timothy J.	La Jolla	CA		

US-CL-CURRENT: 424/9.2; 514/12, 514/21, 514/866, 514/884

Full | Title | Citation | Front | Review | Classification | Date | Reference | Sequences | Attachments KWIC | Draw Desc | Image

---

☐ 5. Document ID: US 5814600 A

L1: Entry 5 of 20 File: USPT Sep 29, 1998

US-PAT-NO: 5814600
DOCUMENT-IDENTIFIER: US 5814600 A

TITLE: Method and composition for treatment of insulin requiring mammals

DATE-ISSUED: September 29, 1998

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Rink; Timothy J.	La Jolla	CA		
Young; Andrew A.	Alpine	CA		

US-CL-CURRENT: 514/4; 514/12, 514/21, 514/3

Full | Title | Citation | Front | Review | Classification | Date | Reference | Sequences | Attachments KWIC | Draw Desc | Image

---

☐ 6. Document ID: US 5739106 A

L1: Entry 6 of 20 File: USPT Apr 14, 1998

US-PAT-NO: 5739106
DOCUMENT-IDENTIFIER: US 5739106 A

TITLE: Appetite regulating compositions

DATE-ISSUED: April 14, 1998

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Rink; Timothy J.	La Jolla	CA	92037	
Young; Andrew A.	Alpine	CA	91901	
Beeley; Nigel Robert Arnold	Solana Beach	CA	92037	
Prickett; Kathryn S.	San Diego	CA	92126	

US-CL-CURRENT: 514/12; 514/16, 514/18, 514/19, 530/303, 530/307, 530/312, 530/324, 530/328, 530/331

Full | Title | Citation | Front | Review | Classification | Date | Reference | Sequences | Attachments KWIC | Draw Desc | Image

---

☐ 7. Document ID: US 5677279 A

L1: Entry 7 of 20 File: USPT Oct 14, 1997

US-PAT-NO: 5677279
DOCUMENT-IDENTIFIER: US 5677279 A

TITLE: Methods and compositions for treating pain with amylin or agonists thereof

DATE-ISSUED: October 14, 1997

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Young; Andrew A.	San Diego	CA		

US-CL-CURRENT: 514/12

Full | Title | Citation | Front | Review | Classification | Date | Reference | Sequences | Attachments KWIC | Draw Desc | Image

---

☐ 8. Document ID: US 5656590 A

L1: Entry 8 of 20 File: USPT Aug 12, 1997

US-PAT-NO: 5656590
DOCUMENT-IDENTIFIER: US 5656590 A

TITLE: Treatment of anorexia and related states

DATE-ISSUED: August 12, 1997

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Rink; Timothy J.	La Jolla	CA		
Young; Andrew A.	San Diego	CA		

US-CL-CURRENT: 514/3; 514/12, 514/4, 530/303

Full | Title | Citation | Front | Review | Classification | Date | Reference | Sequences | Attachments | KWIC | Draw Desc | Image

---

☐ 9. Document ID: US 5527771 A

L1: Entry 9 of 20 File: USPT Jun 18, 1996

US-PAT-NO: 5527771
DOCUMENT-IDENTIFIER: US 5527771 A

TITLE: Methods and Compositions for treatment of diabetes mellitus, hypoglycemia & other conditions

DATE-ISSUED: June 18, 1996

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Beaumont; Kevin	San Diego	CA		
Young; Andrew A.	San Diego	CA		

US-CL-CURRENT: 514/12; 530/307, 530/308

Full | Title | Citation | Front | Review | Classification | Date | Reference | Sequences | Attachments | KWIC | Draw Desc | Image

---

☐ 10. Document ID: US 5508260 A

L1: Entry 10 of 20 File: USPT Apr 16, 1996

US-PAT-NO: 5508260
DOCUMENT-IDENTIFIER: US 5508260 A

TITLE: Methods and compositions for treatment of diabetes mellitus, hypoglycemia, and other conditions

DATE-ISSUED: April 16, 1996

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Beaumont; Kevin	San Diego	CA		
Young; Andrew A.	San Diego	CA		

US-CL-CURRENT: 514/4; 530/303, 530/307

Full | Title | Citation | Front | Review | Classification | Date | Reference | Sequences | Attachments | KWIC | Draw Desc | Image

☐ 11. Document ID: US 5376638 A

L1: Entry 11 of 20 File: USPT Dec 27, 1994

US-PAT-NO: 5376638
DOCUMENT-IDENTIFIER: US 5376638 A

TITLE: Methods for treating renin-related disorders with amylin antagonists

DATE-ISSUED: December 27, 1994

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Young; Andrew A.	San Diego	CA		
Rink; Timothy J.	La Jolla	CA		

US-CL-CURRENT: 514/12; 514/11, 514/13

Full | Title | Citation | Front | Review | Classification | Date | Reference | Sequences | Attachments | KWIC | Draw Desc | Image

☐ 12. Document ID: US 5321008 A

L1: Entry 12 of 20 File: USPT Jun 14, 1994

US-PAT-NO: 5321008
DOCUMENT-IDENTIFIER: US 5321008 A

TITLE: Methods and compositions for treatment of diabetes mellitus, hypoglycemia, and other conditions

DATE-ISSUED: June 14, 1994

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Beaumont; Kevin	San Diego	CA		
Young; Andrew A.	San Diego	CA		

US-CL-CURRENT: 514/4; 514/12, 514/21

Full | Title | Citation | Front | Review | Classification | Date | Reference | Sequences | Attachments | KWIC | Draw Desc | Image

☐ 13. Document ID: WO 9940788 A1

L1: Entry 13 of 20 File: EPAB Aug 19, 1999

PUB-NO: WO009940788A1
DOCUMENT-IDENTIFIER: WO 9940788 A1
TITLE: INOTROPIC AND DIURETIC EFFECTS OF EXENDIN AND GLP-1

PUBN-DATE: August 19, 1999

INVENTOR-INFORMATION:

NAME	COUNTRY
YOUNG, ANDREW A	US
VINE, WILL	US
BEELEY, NIGEL R A	US
PRICKETT, KATHRYN	US

INT-CL (IPC): A01 N 37/18
EUR-CL (EPC): A61K031/00

Full | Title | Citation | Front | Review | Classification | Date | Reference | Sequences | Attachments

KWIC | Draw. Desc | Image

☐ 14. Document ID: WO 9805351 A1

L1: Entry 14 of 20 File: EPAB Feb 12, 1998

PUB-NO: WO009805351A1
DOCUMENT-IDENTIFIER: WO 9805351 A1
TITLE: METHODS FOR REGULATING GASTROINTESTINAL MOTILITY

PUBN-DATE: February 12, 1998

INVENTOR-INFORMATION:

NAME	COUNTRY
YOUNG, ANDREW A	US
GEDULIN, BRONISLAVA	US
BEELEY, NIGEL ROBERT ARNOLD	US
PRICKETT, KATHRYN S	US

INT-CL (IPC): A61 K 38/00; A61 K 38/26; G03 F 5/00; C07 K 2/00; C07 K 5/00
EUR-CL (EPC): C07K014/575; A61K038/22

Full | Title | Citation | Front | Review | Classification | Date | Reference | Sequences | Attachments

KWIC | Draw. Desc | Image

☐ 15. Document ID: WO 9640196 A1

L1: Entry 15 of 20 File: EPAB Dec 19, 1996

PUB-NO: WO009640196A1
DOCUMENT-IDENTIFIER: WO 9640196 A1
TITLE: APPETITE REGULATING COMPOSITIONS

PUBN-DATE: December 19, 1996

INVENTOR-INFORMATION:

NAME	COUNTRY
RINK, TIMOTHY J	US
YOUNG, ANDREW A	US
BEELEY, NIGEL R A	US
PRICKETT, KATHERYN S	US

INT-CL (IPC): A61 K 38/00; C07 K 5/10; C07 K 7/06; C07 K 14/00
EUR-CL (EPC): C07K014/575; A61K038/22, A61K038/22 , A61K038/23 , C07K014/595

Full | Title | Citation | Front | Review | Classification | Date | Reference | Sequences | Attachments

KWIC | Draw. Desc | Image

☐ 16. Document ID: WO 9507098 A1

L1: Entry 16 of 20 File: EPAB Mar 16, 1995

PUB-NO: WO0009507098A1
DOCUMENT-IDENTIFIER: WO 9507098 A1
TITLE: METHODS FOR REGULATING GASTROINTESTINAL MOTILITY

PUBN-DATE: March 16, 1995

INVENTOR-INFORMATION:

NAME	COUNTRY
KOLTERMAN, ORVILLE G	
YOUNG, ANDREW A	
RINK, TIMOTHY J	
BROWN, KATHLEEN KEITING	

INT-CL (IPC): A61 K 38/22; A61 K 38/23
EUR-CL (EPC): A61K038/22; A61K038/23

Full | Title | Citation | Front | Review | Classification | Date | Reference | Sequences | Attachments | KWIC | Draw. Desc | Clip Img | Image

☐ 17. Document ID: WO 9319774 A1

L1: Entry 17 of 20 File: EPAB Oct 14, 1993

PUB-NO: WO0009319774A1
DOCUMENT-IDENTIFIER: WO 9319774 A1
TITLE: AMYLIN AND POSSIBLY INSULIN CONTAINING COMPOSITION FOR THE TREATMENT OF ANOREXIA AND RELATED STATES

PUBN-DATE: October 14, 1993

INVENTOR-INFORMATION:

NAME	COUNTRY
RINK, TIMOTHY J	
YOUNG, ANDREW A	

INT-CL (IPC): A61K 37/02
EUR-CL (EPC): A61K037/02; A61K038/22, A61K038/28

Full | Title | Citation | Front | Review | Classification | Date | Reference | Sequences | Attachments | KWIC | Draw. Desc | Image

☐ 18. Document ID: WO 9220367 A1

L1: Entry 18 of 20 File: EPAB Nov 26, 1992

PUB-NO: WO0009220367A1
DOCUMENT-IDENTIFIER: WO 9220367 A1
TITLE: TREATMENT OF ANOREXIA AND RELATED STATES

PUBN-DATE: November 26, 1992

INVENTOR-INFORMATION:

NAME	COUNTRY
RINK, TIMOTHY J	US
YOUNG, ANDREW A	US

INT-CL (IPC): A61K 37/02
EUR-CL (EPC): A61K038/28; A61K038/22

Full | Title | Citation | Front | Review | Classification | Date | Reference | Sequences | Attachments KWIC | Draw Desc | Image

---

☐ 19. Document ID: WO 9220366 A1

L1: Entry 19 of 20 File: EPAB Nov 26, 1992

PUB-NO: WO009220366A1
DOCUMENT-IDENTIFIER: WO 9220366 A1
TITLE: INSULIN AND AMYLIN CONTAINING COMPOSITION FOR THE TREATMENT OF INSULIN DEFICIENT MAMMALS

PUBN-DATE: November 26, 1992

INVENTOR-INFORMATION:

NAME	COUNTRY
RINK, TIMOTHY J	US
YOUNG, ANDREW A	US

INT-CL (IPC): A61K 37/02
EUR-CL (EPC): A61K037/02; A61K038/22, A61K038/28

Full | Title | Citation | Front | Review | Classification | Date | Reference | Sequences | Attachments KWIC | Draw Desc | Image

---

☐ 20. Document ID: WO 9216222 A1

L1: Entry 20 of 20 File: EPAB Oct 1, 1992

PUB-NO: WO009216222A1
DOCUMENT-IDENTIFIER: WO 9216222 A1
TITLE: METHODS AND COMPOSITIONS FOR TREATMENT OF DIABETES MELLITUS, HYPOGLYCEMIA, AND OTHER CONDITIONS

PUBN-DATE: October 1, 1992

INVENTOR-INFORMATION:

NAME	COUNTRY
BEAUMONT, KEVIN	US
YOUNG, ANDREW A	US

INT-CL (IPC): A61K 37/00; A61K 37/02; A61K 37/26; C07K 5/00; C07K 7/00; C07K 15/00; C07K 17/00
EUR-CL (EPC): A61K038/28

Full | Title | Citation | Front | Review | Classification | Date | Reference | Sequences | Attachments KWIC | Draw Desc | Image

---

Generate Collection | Print

Term	Documents
YOUNG-ANDREW-A$	0
YOUNG-ANDREW-A.DWPI,EPAB,USPT,PGPB.	20
YOUNG-ANDREW-A$.IN..USPT,PGPB,EPAB,DWPI,TDBD.	20
(YOUNG-ANDREW-A$.IN.).USPT,PGPB,EPAB,DWPI,TDBD.	20

Display Format: - Change Format

Previous Page Next Page